SB 987: California Cancer Care Equity Act.
- Session Year: 2021-2022
- House: Senate
- Latest Version Date: 2022-09-27
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services through various health care delivery systems, including managed care pursuant to Medi-Cal managed care plan contracts. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions.
This bill would, for covered benefits under its contract, require a Medi-Cal managed care plan to, among other things, make a good faith effort to contract with at least one National Cancer Institute (NCI)-designated comprehensive cancer center, site affiliated with the NCI Community Oncology Research Program (NCORP), or qualifying academic cancer center, as specified within each county in which the Medi-Cal managed care plan operates, and authorize any eligible enrollee diagnosed with a complex cancer diagnosis to request a referral to any of those centers to receive medically necessary services unless the enrollee chooses a different cancer treatment provider. The bill would require a Medi-Cal managed care plan to notify all enrollees of their right to request a referral to access to care through any of those centers.
The bill would authorize the department to implement, interpret, or make specific the provisions by means of all-county letters or similar guidance, without taking further regulatory action. The bill would require the department, in consultation with stakeholders, to develop a process for updating and further defining a complex cancer diagnosis on a periodic basis. The bill would require the department to seek federal approval to implement those provisions and would require the provisions be implemented only to the extent that necessary federal approvals are obtained.
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services through various health care delivery systems, including managed care pursuant to Medi-Cal managed care plan contracts. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions.
This bill would, for covered benefits under its contract, require a Medi-Cal managed care plan to, among other things, make a good faith effort to contract with at least one National Cancer Institute (NCI)-designated comprehensive cancer center, site affiliated with the NCI Community Oncology Research Program (NCORP), or qualifying academic cancer center, as specified within each county in which the Medi-Cal managed care plan operates, and authorize any eligible enrollee diagnosed with a complex cancer diagnosis to request a referral to any of those centers to receive medically necessary services unless the enrollee chooses a different cancer treatment provider. The bill would require a Medi-Cal managed care plan to notify all enrollees of their right to request a referral to access to care through any of those centers.
The bill would authorize the department to implement, interpret, or make specific the provisions by means of all-county letters or similar guidance, without taking further regulatory action. The bill would require the department, in consultation with stakeholders, to develop a process for updating and further defining a complex cancer diagnosis on a periodic basis. The bill would require the department to seek federal approval to implement those provisions and would require the provisions be implemented only to the extent that necessary federal approvals are obtained.
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services through various health care delivery systems, including managed care pursuant to Medi-Cal managed care plan contracts. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions.
This bill would would, for covered benefits under its contract, require a Medi-Cal managed care plan to to, among other things, make a good-faith good faith effort to include in its contracted provider network contract with at least one National Cancer Institute (NCI)-designated comprehensive cancer center, site affiliated with the NCI Community Oncology Research Program (NCORP), or qualifying academic cancer center, as defined, located within the beneficiarys county of residence or as otherwise specified, and ensure that any beneficiary diagnosed with a complex cancer diagnosis, as defined, is eligible specified within each county in which the Medi-Cal managed care plan operates, and authorize any eligible enrollee diagnosed with a complex cancer diagnosis to request a referral to any of those centers within 15 business days of the diagnosis, unless the beneficiary selects a different cancer treatment provider. to receive medically necessary services unless the enrollee chooses a different cancer treatment provider. The bill would require a Medi-Cal managed care plan to notify all enrollees of their right to request a referral to access to care through any of those centers.
This bill, to the extent necessary federal approvals are obtained and federal financial participation is available, would, among other things, also require a Medi-Cal managed care plan to comply with additional requirements relating to contracting and eligible enrollees ability to request a referral to access services, including, allowing any eligible enrollee diagnosed with a complex cancer diagnosis to request a referral to receive services through any of those centers. The bill would require a Medi-Cal managed care plan to provide notice to an enrollee of their right to request a referral to access care through any of those centers, as specified, and would require the department, in consultation with others, to develop a standard process for notifying enrollees of their right to request a referral to access cancer treatment care through any of those centers.The bill would, beginning January 1, 2023, require each applicable Medi-Cal managed care plan to reimburse a provider of any of those centers furnishing services to a Medi-Cal beneficiary with a complex cancer diagnosis enrolled in that plan, and require each center to accept the payment amount for those services, with the amount being set by the department upon consultation with the plans and centers if the plan and center do not otherwise have an agreed-upon contracted rate.The bill would authorize the department to implement, interpret, or make specific the provisions by means of all-county letters or similar guidance, until any necessary regulations are adopted. without taking further regulatory action. The bill would require the department department, in consultation with stakeholders, to develop a process for updating and further defining a complex cancer diagnosis on a periodic basis, as specified. basis. The bill would require the department to seek federal approval to implement those provisions and would require the provisions be implemented only to the extent that necessary federal approvals are obtained.
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services through various health care delivery systems, including managed care pursuant to Medi-Cal managed care plan contracts. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions.
This bill would require a Medi-Cal managed care plan to make a good-faith effort to include in its contracted provider network at least one National Cancer Institute (NCI)-designated comprehensive cancer center, site affiliated with the NCI Community Oncology Research Program (NCORP), or qualifying academic cancer center, as defined, located within the beneficiarys county of residence or as otherwise specified, and ensure that any beneficiary diagnosed with a complex cancer diagnosis, as defined, is referred eligible to request a referral to any of those centers within 15 business days of the diagnosis, unless the beneficiary selects a different cancer treatment provider.
Existing law also requires a Medi-Cal managed care plan to give a beneficiary timely and adequate notice of an adverse benefit determination, as defined, in writing consistent with specified federal regulations that set forth, among other things, rules for standard and expedited decisions regarding authorization of services.This bill would require a Medi-Cal managed care plan to give a request for, or related to, treatment pursuant to a complex cancer diagnosis to receive an expedited authorization decision, as specified.This bill, to the extent necessary federal approvals are obtained and federal financial participation is available, would, among other things, also require a Medi-Cal managed care plan to comply with additional requirements relating to contracting and eligible enrollees access to services. The bill would require contracts between Medi-Cal managed care plans and applicable health care providers to require the treating provider who determines cancer stage or response to treatment to inform enrollees who receive a complex cancer diagnosis of the right to receive care through any of the above-described centers. ability to request a referral to access services, including, allowing any eligible enrollee diagnosed with a complex cancer diagnosis to request a referral to receive services through any of those centers. The bill would require a Medi-Cal managed care plan to provide written and verbal notice to an enrollee of their right to request a referral to access care through any of those centers, as specified, and would require the department, in consultation with others, to develop a standard written notice and a process for verbally process for notifying enrollees of their right to request a referral to access cancer treatment care through any of those centers.
The bill would, beginning January 1, 2023, require each applicable Medi-Cal managed care plan to reimburse a provider of any of those centers furnishing services to a Medi-Cal beneficiary with a complex cancer diagnosis enrolled in that plan, and require each center to accept the payment amount for those services, with the amount being set by the department upon consultation with the plans and centers if the plan and center do not otherwise have an agreed-upon contracted rate.
The bill would authorize the department to implement, interpret, or make specific the provisions by means of all-county letters or similar guidance, until any necessary regulations are adopted. The bill would require the department to develop a process for updating and further defining a complex cancer diagnosis on a periodic basis, as specified.
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services through various health care delivery systems, including managed care pursuant to Medi-Cal managed care plan contracts. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions.
This bill would require a Medi-Cal managed care plan to make a good-faith effort to include in its contracted provider network at least one National Cancer Institute (NCI)-Designated Cancer Center, as specified, (NCI)-designated comprehensive cancer center, site affiliated with the NCI Community Oncology Research Program (NCORP), or qualifying academic cancer center, as defined, located within the beneficiarys county of residence or as otherwise specified, and ensure that any beneficiary diagnosed with a complex cancer diagnosis, as defined, is referred to an NCI-Designated Cancer Center any of those centers within 15 business days of the diagnosis, unless the beneficiary selects a different cancer treatment provider.
Existing law also requires a Medi-Cal managed care plan to give a beneficiary timely and adequate notice of an adverse benefit determination, as defined, in writing consistent with specified federal regulations that set forth, among other things, rules for standard and expedited decisions regarding authorization of services.
This bill would require a Medi-Cal managed care plan to give a request for, or related to, treatment pursuant to a complex cancer diagnosis to receive an expedited authorization decision, as specified.
This bill, to the extent necessary federal approvals are obtained and federal financial participation is available, would, among other things, also require a Medi-Cal managed care plans plan to comply with additional requirements relating to contracting and eligible enrollees access to services. The bill would require contracts between Medi-Cal managed care plans and primary care providers to require the diagnosing or applicable health care providers to require the treating provider who determines cancer stage or response to treatment to inform enrollees who receive a complex cancer diagnosis of the right to receive care through an NCI-Designated Cancer Center. any of the above-described centers. The bill would require a Medi-Cal managed care plan to provide written and verbal notice to an enrollee of their right to access care through an NCI-Designated Cancer Center, any of those centers, as specified, and would require the department, in consultation with others, to develop a standard written notice and a process for verbally notifying enrollees of their right to access cancer treatment care through an NCI-Designated Cancer Center. any of those centers.
The bill would, beginning January 1, 2023, require each applicable Medi-Cal managed care plan to reimburse an NCI-Designated Cancer Center provider a provider of any of those centers furnishing services to a Medi-Cal beneficiary with a complex cancer diagnosis enrolled in that plan, and require each NCI-Designated Cancer Center center to accept the payment amount for those services, with the amount being set by the department upon consultation with the plans and centers if the plan and center do not otherwise have an agreed-upon contracted rate.
The bill would authorize the department to implement, interpret, or make specific the provisions by means of all-county letters or similar guidance, until any necessary regulations are adopted. The bill would require the department to develop a process for updating and further defining a complex cancer diagnosis on a periodic basis, as specified.
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services through various health care delivery systems, including managed care pursuant to Medi-Cal managed care plan contracts. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions.
This bill would require a Medi-Cal managed care plan to include in its contracted provider network at least one National Cancer Institute (NCI) Designated (NCI)-Designated Cancer Center, as specified, and ensure that any beneficiary diagnosed with a complex cancer diagnosis, as defined, is referred to an NCI-Designated Cancer Center within 15 business days of the diagnosis, unless the beneficiary selects a different cancer treatment provider.
Existing law also requires a Medi-Cal managed care plan to give a beneficiary timely and adequate notice of an adverse benefit determination, as defined, in writing consistent with specified federal regulations that set forth, among other things, rules for standard and expedited decisions regarding authorization of services.
This bill would require a Medi-Cal managed care plan to give a request for, or related to, treatment pursuant to a complex cancer diagnosis to receive an expedited authorization decision, as specified.
This bill, to the extent necessary federal approvals are obtained and federal financial participation is available, would, among other things, also require Medi-Cal managed care plans to comply with additional requirements, including ensuring that access to an NCI-Designated Cancer Center occurs only at the primary Medi-Cal managed care plan level. requirements relating to contracting and eligible enrollees access to services. The bill would require contracts between Medi-Cal managed care plans and primary care providers to require primary care physicians to inform enrollees who receive a complex cancer diagnosis of the enrollees health status, medical care, or treatment options, as specified. the diagnosing or treating provider who determines cancer stage or response to treatment to inform enrollees who receive a complex cancer diagnosis of the right to receive care through an NCI-Designated Cancer Center. The bill would require a Medi-Cal managed care plan to provide written and verbal notice to an enrollee of their right to access care through an NCI-Designated Cancer center, Center, as specified, and would require the department, in consultation with others, to develop a standard written notice and a process for verbally notifying enrollees of their right to access cancer treatment care through an NCI-Designated Cancer Center. The
The bill would, beginning January 1, 2023, require each applicable Medi-Cal managed care plan to reimburse an NCI-Designated Cancer Center provider furnishing services to a Medi-Cal beneficiary with a complex cancer diagnosis enrolled in that plan, and require each NCI-Designated Cancer Center to accept the payment amount for those services, with the amount being set by the department upon consultation with the plans and centers if the plan and center do not otherwise have an agreed-upon contracted rate.
The bill would authorize the department to implement, interpret, or make specific the provisions by means of all-county letters or similar guidance. guidance, until any necessary regulations are adopted. The bill would require the department to develop a process for updating and further defining a complex cancer diagnosis on a periodic basis, as specified.
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services through various health care delivery systems, including managed care pursuant to Medi-Cal managed care plan contracts. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions.
Existing law establishes certain time and distance and appointment time standards for specified Medi-Cal managed care covered services, consistent with federal regulations relating to network adequacy standards, to ensure that those services are available and accessible to enrollees of Medi-Cal managed care plans in a timely manner, as specified. Existing law repeals these provisions on January 1, 2023.This bill would extend the repeal date for those provisions until January 1, 2028.This bill would require a Medi-Cal managed care plan to include in its contracted provider network at least one National Cancer Institute (NCI) Designated Cancer Center, as specified, and ensure that any beneficiary diagnosed with a complex cancer diagnosis, as defined, is referred to an NCI-Designated Cancer Center within 15 business days of the diagnosis, unless the beneficiary selects a different cancer treatment provider.
Existing law also requires a Medi-Cal managed care plan to give a beneficiary timely and adequate notice of an adverse benefit determination, as defined, in writing consistent with specified federal regulations that set forth, among other things, rules for standard and expedited decisions regarding authorization of services.
This bill would require a Medi-Cal managed care plan to give a request for, or related to, treatment pursuant to a complex cancer diagnosis to receive an expedited authorization decision, as specified.
This bill, to the extent necessary federal approvals are obtained and federal financial participation is available, would, among other things, also require Medi-Cal managed care plans to comply with additional requirements, including ensuring that access to an NCI-Designated Cancer Center occurs only at the primary Medi-Cal managed care plan level. The bill would require contracts between Medi-Cal managed care plans and primary care providers to require primary care physicians to inform enrollees who receive a complex cancer diagnosis of the enrollees health status, medical care, or treatment options, as specified. The bill would require a Medi-Cal managed care plan to provide written and verbal notice to an enrollee of their right to access care through an NCI-Designated Cancer center, and would require the department, in consultation with others, to develop a standard written notice and a process for verbally notifying enrollees of their right to access cancer treatment care through an NCI-Designated Cancer Center. The bill would authorize the department to implement, interpret, or make specific the provisions by means of all-county letters or similar guidance.
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services through various health care delivery systems, including managed care pursuant to Medi-Cal managed care plan contracts. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions.
Existing law establishes certain time and distance and appointment time standards for specified Medi-Cal managed care covered services, consistent with federal regulations relating to network adequacy standards, to ensure that those services are available and accessible to enrollees of Medi-Cal managed care plans in a timely manner, as specified. Existing law repeals these provisions on January 1, 2023.
This bill would extend the repeal date for those provisions until January 1, 2028.
This act shall be known, and may be cited, as the California Cancer Care Equity Act.
SEC. 2.(a)The Legislature finds and declares all of the following:
(1)Effective treatment of complex cancers relies on the accuracy of initial diagnosis, timeliness of intervention, choice of therapy, collaboration among multiple experts, and access to appropriate clinical trials or emerging therapies.
(2)The type, duration and complexity of treatment required to meet the needs of patients with complex cancer diagnoses can vary substantially depending on the type and subtype of cancer.
(3)National Cancer Institute (NCI)-designated comprehensive cancer centers are recognized for their scientific leadership, resources, and exceptional depth and breadth of transdisciplinary research that bridges the fields of prevention, cancer control, and population science.
(4)The NCI Community Oncology Research Program (NCORP) is a national network that brings cancer clinical trials and care delivery studies to patients in their own communities and contributes to improved patient outcomes and a reduction in cancer disparities for all people.
(5)Varying levels of access to quality cancer care correlated with socioeconomic status lead to disparities in cancer outcomes, disfavoring the most vulnerable and disadvantaged patients.
(b)It is the intent of the Legislature that a Medi-Cal managed care beneficiary who has received a complex cancer diagnosis will be eligible to receive and able to access the services of an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.
SEC. 3.Section 14197.45 is added to the Welfare and Institutions Code, to read:14197.45.(a)Nothwithstanding any other law, for covered benefits under its contract, as applicable, a Medi-Cal managed care plan shall comply with all of the following:
(1)Make a good faith effort to contract with at least one National Cancer Institute (NCI)-designated comprehensive cancer center, site affiliated with the NCI Community Oncology Research Program (NCORP), or qualifying academic cancer center, within its contracted provider network and its subcontracted provider network, if applicable, within each county in which the Medi-Cal managed care plan operates, for provision of services to any eligible enrollee diagnosed with a complex cancer diagnosis. For purposes of this paragraph the NCI-designated comprehensive cancer center, NCORP affiliated site, or qualifying academic cancer center shall enroll in the Medi-Cal program if there is a state-level enrollment pathway, or the Medi-Cal managed care plan shall vet the qualifications of the facility to ensure they can meet the standards of participation required to contract with a Medi-Cal managed care plan.
(2)(A)Allow any eligible enrollee diagnosed with a complex cancer diagnosis to request a referral to receive medically necessary services through any of the following in-network providers unless the enrollee chooses a different cancer treatment provider:
(i)An NCI-designated comprehensive cancer center.
(ii)An NCORP-affiliated site.
(iii)A qualifying academic cancer center.
(B)(i)If the Medi-Cal managed care plan is unsuccessful in its good faith contracting efforts pursuant to paragraph (1), the Medi-Cal managed care plan shall allow an enrollee to request a referral to receive medically necessary services through an out-of-network NCI-designated comprehensive cancer center, out-of-network NCORP-affiliated site, or out-of-network qualifying academic cancer center, unless the enrollee chooses a different cancer treatment provider.
(ii)Clause (i) shall only apply if the Medi-Cal managed care plan and the out-of-network NCI-designated comprehensive cancer center, out-of-network NCORP-affiliated site, or out-of-network qualifying academic cancer center come to agreement with respect to payment.
(3)(A)After approving a referral request pursuant to paragraph (2), allow an eligible enrollee diagnosed with a complex cancer diagnosis to access oncology, hematology, or other relevant specialists through a contracted NCI-designated comprehensive cancer center, a contracted NCORP-affiliated site, or a contracted qualifying academic cancer center, for the enrollees condition and identified needs as medically necessary.
(B)If the NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center refers an enrollee with a complex cancer condition to an out-of-network specialist pursuant to subparagraph (B) of paragraph (2), this paragraph shall only apply if the Medi-Cal managed care plan and the out-of-network specialist come to an agreement with respect to payment.
(4)A denial of an enrollees referral request shall be based upon a determination by the treating provider that the request to receive services at an NCIdesignated comprehensive cancer center, or NCORP affiliated site, or a qualifying academic cancer center is not medically necessary, the requested services are not available at, or not applicable to, the enrollees cancer diagnosis at the requested NCI-designated comprehensive cancer center, NCORP affiliated site, or a qualifying academic cancer center site, or the NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center is an out-of-network provider and the Medi-Cal managed care plan and the out-of-network NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center are unable to come to agreement with the respect to payment.
(5)Ensure that the services of an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center available to an eligible enrollee are sufficient in amount, duration, and scope as medically necessary for the treatment of the enrollees condition.
(6)Refrain from arbitrarily denying or reducing the amount, duration, or scope of required services solely because of diagnosis, type of illness, or condition of the enrollee.
(b)A Medi-Cal managed care plan shall notify all enrollees of their right to request a referral to access care through an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center, if they are diagnosed with a complex cancer diagnosis.
(c)For the purposes of this section, the following definitions apply:
(1)(A)Complex cancer diagnosis means a diagnosis for which there is no standard FDA-approved treatment or for which known highly effective therapy for metastatic cancer has failed and any of the following diagnoses: hematological malignancies, acute leukemia, advanced, relapsed, refractory non-Hodgkin lymphoma and multiple myeloma, including BPDCN and T-cell leukemias and lymphomas, and advanced stage, relapsed solid tumors refractory to standard FDA-approved treatment options, advanced stage rare solid tumors for which there is no known effective standard treatment options, or any other condition as determined pursuant to paragraph (2) of subdivision (d). Advanced stage cancer means stage IV metastatic cancer.
(B)The department is authorized to periodically update and further define complex cancer diagnosis pursuant to the process outlined in subdivision (d).
(2)Eligible enrollee means an individual enrolled with a particular Medi-Cal managed care plan who receives a complex cancer diagnosis.
(3)National Cancer Institute (NCI) Community Oncology Research Program (NCORP) affiliated site is a cancer center that has received an approved grant from NCI through NCORP that provides cancer clinical trials and care delivery studies.
(4)NCI-designated comprehensive cancer center is a cancer center that meets ongoing standards for cancer prevention, clinical services, and research, as determined by regular reviews and evaluations by NCI.
(5)Qualifying academic cancer center is a research and clinical cancer center that meets all the following criteria:
(A)It is an institution with a medical oncology or hematology subspecialty expertise in each of the diagnoses included in paragraph (1).
(B)It has a portfolio of phases 1, 2, and 3 clinical trials available for eligible enrollees.
(C)It provides fellowship programs in medical oncology, hematology or hematological oncology, radiation oncology, or a surgical oncology specialty.
(D)It provides inpatient and outpatient supportive care services.
(E)It covers clinical, anatomic, and molecular pathology with subspecialty expertise for each of the cancer types included in paragraph (1).
(F)It provides a program accredited by the American College of Surgeons (ACS) Commission on Cancer (CoC).
(G)It has accreditation for the main campus by the Foundation for the Accreditation of Cellular Therapy.
(d)(1)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section, in whole or in part, by means of all-county letters, plan letters, provider bulletins, information notices, or other similar guidance, without taking further regulatory action.
(2)The department, in consultation with stakeholders, shall develop a process for updating and further defining a complex cancer diagnosis on a periodic basis.
(e)The department shall seek any federal approvals it deems necessary to implement this section. This section shall be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and is not otherwise jeopardized.
(f)For purposes of implementing this section, the department may enter into an exclusive or nonexclusive contract, or amend existing contracts, on a bid or negotiated basis. Contracts entered into or amended pursuant to this section shall be exempt from Chapter 6 (commencing with Section 10100) of Division 2 of the Public Contract Code, and shall be exempt from the review or approval of any division of the Department of General Services.
This act shall be known, and may be cited, as the California Cancer Care Equity Act.
SEC. 2.(a)The Legislature finds and declares all of the following:
(1)Effective treatment of complex cancers relies on the accuracy of initial diagnosis, timeliness of intervention, choice of therapy, collaboration among multiple experts, and access to appropriate clinical trials or emerging therapies.
(2)The type, duration and complexity of treatment required to meet the needs of patients with complex cancer diagnoses can vary substantially depending on the type and subtype of cancer.
(3)National Cancer Institute (NCI)-designated comprehensive cancer centers are recognized for their scientific leadership, resources, and exceptional depth and breadth of transdisciplinary research that bridges the fields of prevention, cancer control, and population science.
(4)The NCI Community Oncology Research Program (NCORP) is a national network that brings cancer clinical trials and care delivery studies to patients in their own communities and contributes to improved patient outcomes and a reduction in cancer disparities for all people.
(5)Varying levels of access to quality cancer care correlated with socioeconomic status lead to disparities in cancer outcomes, disfavoring the most vulnerable and disadvantaged patients.
(b)It is the intent of the Legislature that a Medi-Cal managed care beneficiary who has received a complex cancer diagnosis will be eligible to receive and able to access the services of an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.
SEC. 3.Section 14197.45 is added to the Welfare and Institutions Code, to read:14197.45.(a)Nothwithstanding any other law, for covered benefits under its contract, as applicable, a Medi-Cal managed care plan shall comply with all of the following:
(1)Make a good faith effort to contract with at least one National Cancer Institute (NCI)-designated comprehensive cancer center, site affiliated with the NCI Community Oncology Research Program (NCORP), or qualifying academic cancer center, within its contracted provider network and its subcontracted provider network, if applicable, within each county in which the Medi-Cal managed care plan operates, for provision of services to any eligible enrollee diagnosed with a complex cancer diagnosis. For purposes of this paragraph the NCI-designated comprehensive cancer center, NCORP affiliated site, or qualifying academic cancer center shall enroll in the Medi-Cal program if there is a state-level enrollment pathway, or the Medi-Cal managed care plan shall vet the qualifications of the facility to ensure they can meet the standards of participation required to contract with a Medi-Cal managed care plan.
(2)(A)Allow any eligible enrollee diagnosed with a complex cancer diagnosis to request a referral to receive medically necessary services through any of the following in-network providers unless the enrollee chooses a different cancer treatment provider:
(i)An NCI-designated comprehensive cancer center.
(ii)An NCORP-affiliated site.
(iii)A qualifying academic cancer center.
(B)(i)If the Medi-Cal managed care plan is unsuccessful in its good faith contracting efforts pursuant to paragraph (1), the Medi-Cal managed care plan shall allow an enrollee to request a referral to receive medically necessary services through an out-of-network NCI-designated comprehensive cancer center, out-of-network NCORP-affiliated site, or out-of-network qualifying academic cancer center, unless the enrollee chooses a different cancer treatment provider.
(ii)Clause (i) shall only apply if the Medi-Cal managed care plan and the out-of-network NCI-designated comprehensive cancer center, out-of-network NCORP-affiliated site, or out-of-network qualifying academic cancer center come to agreement with respect to payment.
(3)(A)After approving a referral request pursuant to paragraph (2), allow an eligible enrollee diagnosed with a complex cancer diagnosis to access oncology, hematology, or other relevant specialists through a contracted NCI-designated comprehensive cancer center, a contracted NCORP-affiliated site, or a contracted qualifying academic cancer center, for the enrollees condition and identified needs as medically necessary.
(B)If the NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center refers an enrollee with a complex cancer condition to an out-of-network specialist pursuant to subparagraph (B) of paragraph (2), this paragraph shall only apply if the Medi-Cal managed care plan and the out-of-network specialist come to an agreement with respect to payment.
(4)A denial of an enrollees referral request shall be based upon a determination by the treating provider that the request to receive services at an NCIdesignated comprehensive cancer center, or NCORP affiliated site, or a qualifying academic cancer center is not medically necessary, the requested services are not available at, or not applicable to, the enrollees cancer diagnosis at the requested NCI-designated comprehensive cancer center, NCORP affiliated site, or a qualifying academic cancer center site, or the NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center is an out-of-network provider and the Medi-Cal managed care plan and the out-of-network NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center are unable to come to agreement with the respect to payment.
(5)Ensure that the services of an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center available to an eligible enrollee are sufficient in amount, duration, and scope as medically necessary for the treatment of the enrollees condition.
(6)Refrain from arbitrarily denying or reducing the amount, duration, or scope of required services solely because of diagnosis, type of illness, or condition of the enrollee.
(b)A Medi-Cal managed care plan shall notify all enrollees of their right to request a referral to access care through an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center, if they are diagnosed with a complex cancer diagnosis.
(c)For the purposes of this section, the following definitions apply:
(1)(A)Complex cancer diagnosis means a diagnosis for which there is no standard FDA-approved treatment or for which known highly effective therapy for metastatic cancer has failed and any of the following diagnoses: hematological malignancies, acute leukemia, advanced, relapsed, refractory non-Hodgkin lymphoma and multiple myeloma, including BPDCN and T-cell leukemias and lymphomas, and advanced stage, relapsed solid tumors refractory to standard FDA-approved treatment options, advanced stage rare solid tumors for which there is no known effective standard treatment options, or any other condition as determined pursuant to paragraph (2) of subdivision (d). Advanced stage cancer means stage IV metastatic cancer.
(B)The department is authorized to periodically update and further define complex cancer diagnosis pursuant to the process outlined in subdivision (d).
(2)Eligible enrollee means an individual enrolled with a particular Medi-Cal managed care plan who receives a complex cancer diagnosis.
(3)National Cancer Institute (NCI) Community Oncology Research Program (NCORP) affiliated site is a cancer center that has received an approved grant from NCI through NCORP that provides cancer clinical trials and care delivery studies.
(4)NCI-designated comprehensive cancer center is a cancer center that meets ongoing standards for cancer prevention, clinical services, and research, as determined by regular reviews and evaluations by NCI.
(5)Qualifying academic cancer center is a research and clinical cancer center that meets all the following criteria:
(A)It is an institution with a medical oncology or hematology subspecialty expertise in each of the diagnoses included in paragraph (1).
(B)It has a portfolio of phases 1, 2, and 3 clinical trials available for eligible enrollees.
(C)It provides fellowship programs in medical oncology, hematology or hematological oncology, radiation oncology, or a surgical oncology specialty.
(D)It provides inpatient and outpatient supportive care services.
(E)It covers clinical, anatomic, and molecular pathology with subspecialty expertise for each of the cancer types included in paragraph (1).
(F)It provides a program accredited by the American College of Surgeons (ACS) Commission on Cancer (CoC).
(G)It has accreditation for the main campus by the Foundation for the Accreditation of Cellular Therapy.
(d)(1)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section, in whole or in part, by means of all-county letters, plan letters, provider bulletins, information notices, or other similar guidance, without taking further regulatory action.
(2)The department, in consultation with stakeholders, shall develop a process for updating and further defining a complex cancer diagnosis on a periodic basis.
(e)The department shall seek any federal approvals it deems necessary to implement this section. This section shall be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and is not otherwise jeopardized.
(f)For purposes of implementing this section, the department may enter into an exclusive or nonexclusive contract, or amend existing contracts, on a bid or negotiated basis. Contracts entered into or amended pursuant to this section shall be exempt from Chapter 6 (commencing with Section 10100) of Division 2 of the Public Contract Code, and shall be exempt from the review or approval of any division of the Department of General Services.
This act shall be known, and may be cited, as the California Cancer Care Equity Act.
SEC. 2.(a)The Legislature finds and declares all of the following:
(1)Effective treatment of complex cancers relies on the accuracy of initial diagnosis, timeliness of intervention, choice of therapy, collaboration among multiple experts, and access to appropriate clinical trials or emerging therapies.
(2)The type, duration and complexity of treatment required to meet the needs of patients with complex cancer diagnoses can vary substantially depending on the type and subtype of cancer.
(2)(3)National Cancer Institute (NCI)-designated comprehensive cancer centers are recognized for their scientific leadership, resources, and exceptional depth and breadth of transdisciplinary research that bridges the fields of prevention, cancer control, and population science.
(3)(4)The NCI Community Oncology Research Program (NCORP) is a national network that brings cancer clinical trials and care delivery studies to patients in their own communities and contributes to improved patient outcomes and a reduction in cancer disparities for all people.
(4)(5)Varying levels of access to quality cancer care correlated with socioeconomic status lead to disparities in cancer outcomes, disfavoring the most vulnerable and disadvantaged patients.
(b)It is the intent of the Legislature that a Medi-Cal managed care beneficiary who has received a complex cancer diagnosis will be eligible to receive and able to access the services of an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.
SEC. 3.Section 14197.01 is added to the Welfare and Institutions Code, to read:14197.01.(a)Notwithstanding any other law, for covered benefits under its contract, as applicable, a Medi-Cal managed care plan shall do both of the following:(1)Make a good-faith effort to include in its contracted provider network at least one National Cancer Institute (NCI)-designated comprehensive cancer center, site affiliated with the NCI Community Oncology Research Program (NCORP), or qualifying academic cancer center, located within the beneficiarys county of residence or, if none exists in that county, located within the nearest county that has an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.(2)Ensure that any beneficiary diagnosed with a complex cancer diagnosis, as defined in paragraph (1) of subdivision (d) of Section 14197.45, is eligible to request a referral to an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center within 15 business days of the diagnosis, unless the beneficiary chooses a different cancer treatment provider.(b)For purposes of this section, NCI-designated comprehensive cancer center, NCORP-affiliated site, qualifying academic cancer center, and complex cancer diagnosis shall have the same corresponding meanings as set forth in Section 14197.45.SEC. 4.SEC. 3.Section 14197.45 is added to the Welfare and Institutions Code, to read:14197.45.(a)A Nothwithstanding any other law, for covered benefits under its contract, as applicable, a Medi-Cal managed care plan shall comply with all of the following:
(1)Make a good-faith good faith effort to contract with at least one National Cancer Institute (NCI)-designated comprehensive cancer center, site affiliated with the NCI Community Oncology Research Program (NCORP), or qualifying academic cancer center, within its primary network its contracted provider network and its subcontracted provider network, if applicable, within each county in which the Medi-Cal managed care plan operates, for provision of services to any eligible enrollee diagnosed with a complex cancer diagnosis. For purposes of this paragraph the NCI-designated comprehensive cancer center, NCORP affiliated site, or qualifying academic cancer center shall enroll in the Medi-Cal program if there is a state-level enrollment pathway, or the Medi-Cal managed care plan shall vet the qualifications of the facility to ensure they can meet the standards of participation required to contract with a Medi-Cal managed care plan.
(2)(A)Allow any eligible enrollee diagnosed with a complex cancer diagnosis to request a referral to receive services through an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center. medically necessary services through any of the following in-network providers unless the enrollee chooses a different cancer treatment provider:
(i)An NCI-designated comprehensive cancer center.
(ii)An NCORP-affiliated site.
(iii)A qualifying academic cancer center.
(B)(i)If the Medi-Cal managed care plan is unsuccessful in its good faith contracting efforts pursuant to paragraph (1), the Medi-Cal managed care plan shall allow an enrollee to request a referral to receive medically necessary services through an out-of-network NCI-designated comprehensive cancer center, out-of-network NCORP-affiliated site, or out-of-network qualifying academic cancer center, unless the enrollee chooses a different cancer treatment provider.
(ii)Clause (i) shall only apply if the Medi-Cal managed care plan and the out-of-network NCI-designated comprehensive cancer center, out-of-network NCORP-affiliated site, or out-of-network qualifying academic cancer center come to agreement with respect to payment.
(3)After a referral (A)After approving a referral request pursuant to paragraph (2), allow an eligible enrollee diagnosed with a complex cancer diagnosis to access oncology, hematology, or other relevant specialists through an a contracted NCI-designated comprehensive cancer center, a contracted NCORP-affiliated site, or a contracted qualifying academic cancer center, for the enrollees condition and identified needs. needs as medically necessary.
(B)If the NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center refers an enrollee with a complex cancer condition to an out-of-network specialist pursuant to subparagraph (B) of paragraph (2), this paragraph shall only apply if the Medi-Cal managed care plan and the out-of-network specialist come to an agreement with respect to payment.
(4)Inform an enrollee within seven calendar days of the enrollee receiving a complex cancer diagnosis of the enrollees ability to request a referral to receive cancer care at an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center, and grievance, appeal, and fair hearing procedures and timeframes should the enrollees request for referral be denied. A Medi-Cal managed care plan shall also inform the enrollee of their ability to access transportation services if needed to access their care pursuant to subdivision (ad) of Section 14132.(5)(4)A denial of an enrollees referral request shall be based upon a determination by the treating provider that the request to receive services at an NCIdesignated comprehensive cancer center, or NCORP affiliated site, or a qualifying academic cancer center is not medically necessary, the requested services are not available at, or not applicable to, the enrollees cancer diagnosis at the requested NCI-designated comprehensive cancer center, NCORP affiliated site, or a qualifying academic cancer center site. site, or the NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center is an out-of-network provider and the Medi-Cal managed care plan and the out-of-network NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center are unable to come to agreement with the respect to payment.
(6)(5)Ensure that the services of an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center available to an eligible enrollee are sufficient in amount, duration, and scope to reasonably achieve the purpose for which the services are furnished. as medically necessary for the treatment of the enrollees condition.
(7)(6)Refrain from arbitrarily denying or reducing the amount, duration, or scope of required services solely because of diagnosis, type of illness, or condition of the beneficiary. enrollee.
(b)(1)A Medi-Cal managed care plan shall provide notice to notify all enrollees of their right to request a referral to access care through a contracted an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center, if they are diagnosed with a complex cancer diagnosis.
(2)The department, in consultation with representatives of NCI-designated comprehensive cancer centers, NCORP-affiliated sites, qualifying academic cancer centers, patients or patient advocates, and Medi-Cal managed care plans, shall develop a standard process for notifying enrollees of their right to request referral to access cancer treatment care through an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.(c)(1)Beginning January 1, 2023, each applicable Medi-Cal managed care plan shall reimburse an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center provider furnishing services to a Medi-Cal beneficiary with a complex cancer diagnosis enrolled in that plan, and each NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center shall accept the payment amount for those services, the amount set by the department upon consultation with the Medi-Cal managed care plans, NCI-designated comprehensive cancer centers, NCORP-affiliated sites, and qualifying academic cancer centers, if the Medi-Cal managed care plan and the NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center do not otherwise have an agreed-upon contracted rate.(2)For contract periods during which paragraph (1) is implemented, capitation rates paid by the department to a Medi-Cal managed care plan shall be actuarially sound and shall account for the payment levels described in paragraph (1). The department may require Medi-Cal managed care plans and NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center providers to submit information the department deems necessary to implement this subdivision, at the times and in the form and manner specified by the department.(3)For contract periods during which paragraph (1) is implemented, the department shall develop and implement risk mitigation strategies, such as a risk corridor or supplemental capitation payment. Risk mitigation strategies shall be developed in consultation with the Medi-Cal managed care plans and NCI-designated comprehensive cancer centers, NCORP-affiliated sites, and qualifying academic cancer centers.(d)(c)For the purposes of this section, the following definitions apply:
(1)(A)Complex cancer diagnosis means a diagnosis for which there is no standard FDA-approved treatment or for which known highly effective therapy for metastatic cancer has failed and any of the following diagnoses: hematological malignancies, acute leukemia, advanced, relapsed, refractory non-Hodgkin lymphoma and multiple myeloma, rare hematological malignancies, including BPDCN and T-cell leukemias and lymphomas, and advanced stage, relapsed solid tumors refractory to standard FDA-approved treatment options, advanced stage rare solid tumors for which there is no known effective standard treatment options, or any other condition as determined pursuant to subparagraph (B) of paragraph (1) of subdivision (e). paragraph (2) of subdivision (d). Advanced stage cancer means stage IV metastatic cancer.
(B)The department is authorized to periodically update and further define complex cancer diagnosis pursuant to the process outlined in subdivision (d).
(2)Eligible enrollee means an individual enrolled with a particular Medi-Cal managed care plan who receives a complex cancer diagnosis.
(3)National Cancer Institute (NCI) Community Oncology Research Program (NCORP) affiliated site is a cancer center that has received an approved grant from NCI through NCORP that provides cancer clinical trials and care delivery studies.
(4)NCI-designated comprehensive cancer center is a cancer center that meets ongoing standards for cancer prevention, clinical services, and research, as determined by regular reviews and evaluations by NCI.
(5)Qualifying academic cancer center is a research and clinical cancer center that meets all the following criteria:
(A)It is an institution with a medical oncology or hematology subspecialty expertise in each of the diagnoses included in paragraph (1).
(B)It has a portfolio of phases 1, 2, and 3 clinical trials for each of the cancer types included in paragraph (1). available for eligible enrollees.
(C)It provides fellowship programs in medical oncology, hematology or hematological oncology, radiation oncology, or a surgical oncology specialty.
(D)It provides inpatient and outpatient supportive care services.
(E)It covers clinical, anatomic, and molecular pathology with subspecialty expertise for each of the cancer types included in paragraph (1).
(F)It provides a program accredited by the American College of Surgeons (ACS) Commission on Cancer (CoC).
(G)It has accreditation for the main campus by the Foundation for the Accreditation of Cellular Therapy.
(e)(1)(A)(d)(1)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section, in whole or in part, by means of all-county letters, plan letters, provider bulletins, information notices, or other similar guidance, until any necessary regulations are adopted. without taking further regulatory action.
(B)(2)The department department, in consultation with stakeholders, shall develop a process for updating and further defining a complex cancer diagnosis on a periodic basis. The process shall include an advisory committee consisting of experts in the field of oncology and stakeholders, including, but not limited to, oncologists, representatives of NCI-designated comprehensive cancer centers, NCORP-affiliated sites, and qualifying academic cancer centers, representatives of Medi-Cal managed care plans, and cancer patient advocacy groups.
(2)(e)The department shall seek any federal approvals it deems necessary to implement this section. This section shall be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and is not otherwise jeopardized.
(f)For purposes of implementing this section, the department may enter into an exclusive or nonexclusive contract, or amend existing contracts, on a bid or negotiated basis. Contracts entered into or amended pursuant to this section shall be exempt from Chapter 6 (commencing with Section 10100) of Division 2 of the Public Contract Code, and shall be exempt from the review or approval of any division of the Department of General Services.
This act shall be known, and may be cited, as the California Cancer Care Equity Act.
SEC. 2.(a)The Legislature finds and declares all of the following:
(1)Effective treatment of complex cancers relies on the accuracy of initial diagnosis, timeliness of intervention, choice of therapy, collaboration among multiple experts, and access to appropriate clinical trials or emerging therapies.
(2)National Cancer Institute (NCI)-designated comprehensive cancer centers are recognized for their scientific leadership, resources, and exceptional depth and breadth of transdisciplinary research that bridges the fields of prevention, cancer control, and population science.
(3)The NCI Community Oncology Research Program (NCORP) is a national network that brings cancer clinical trials and care delivery studies to patients in their own communities and contributes to improved patient outcomes and a reduction in cancer disparities for all people.
(4)Varying levels of access to quality cancer care correlated with socioeconomic status lead to disparities in cancer outcomes, disfavoring the most vulnerable and disadvantaged patients.
(b)It is the intent of the Legislature that a Medi-Cal managed care beneficiary who has received a complex cancer diagnosis will be eligible to receive and able to access the services of an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.
SEC. 3.Section 14197.01 is added to the Welfare and Institutions Code, to read:14197.01.(a)Notwithstanding any other law, for covered benefits under its contract, as applicable, a Medi-Cal managed care plan shall do both of the following:
(1)Make a good-faith effort to include in its contracted provider network at least one National Cancer Institute (NCI)-designated comprehensive cancer center, site affiliated with the NCI Community Oncology Research Program (NCORP), or qualifying academic cancer center, located within the beneficiarys county of residence or, if none exists in that county, located within the nearest county that has an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.
(2)Ensure that any beneficiary diagnosed with a complex cancer diagnosis is referred diagnosis, as defined in paragraph (1) of subdivision (d) of Section 14197.45, is eligible to request a referral to an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center within 15 business days of the diagnosis, unless the beneficiary chooses a different cancer treatment provider.
(b)For purposes of this section, NCI-designated comprehensive cancer center, NCORP-affiliated site, qualifying academic cancer center, and complex cancer diagnosis shall have the same corresponding meanings as set forth in Section 14197.45.
SEC. 4.Section 14197.3 of the Welfare and Institutions Code is amended to read:14197.3.(a)A Medi-Cal managed care plan shall give a beneficiary timely and adequate notice of an adverse benefit determination in writing consistent with the requirements in Sections 438.404, 438.408, and 438.10, and 438.210 of Title 42 of the Code of Federal Regulations. For purposes of this subdivision, adverse benefit determination means either of the following:(1)Any action described in Section 10950.(2)Any health care service eligible for coverage and payment under a Medi-Cal managed care plan contract that has been denied, modified, or delayed by a decision of the Medi-Cal managed care plan, or by one of its contracting providers.(b)Except as provided in subdivision (c), a Medi-Cal managed care plan shall resolve an appeal no more than 30 calendar days from the day the Medi-Cal managed care plan receives the appeal.(c)A Medi-Cal managed care plan shall resolve an expedited appeal no longer than 72 hours after the Medi-Cal managed care plan receives the appeal. A Medi-Cal managed care plan shall establish and maintain an expedited review process for a beneficiary or the beneficiarys provider to request an expedited resolution of an appeal based on any of the following circumstances:(1)If the Medi-Cal managed care plan determines, for a request from the beneficiary, or the provider indicates, in making the request on the beneficiarys behalf or supporting the beneficiarys request, that taking the time for a standard resolution under the timeframe described in subdivision (b) could seriously jeopardize the beneficiarys life, physical or mental health, or ability to attain, or regain, maximum function.(2)When the beneficiarys condition is such that the beneficiary faces an imminent and serious threat to the beneficiarys health, including, but not limited to, the potential loss of life, limb, or other major bodily function, or the timeframe described in subdivision (b) would be detrimental to the beneficiarys life or health or could jeopardize the beneficiarys ability to regain maximum function.(3)When a request from the beneficiary or provider is for, or related to, treatment pursuant to a complex cancer diagnosis, as defined in paragraph (1) of subdivision (e) of Section 14197.45.(d)For purposes of paragraph (3) of subdivision (c), a Medi-Cal managed care plan shall give a request for, or related to, treatment pursuant to a complex cancer diagnosis, as defined in paragraph (1) of subdivision (e) of Section 14197.45, an expedited authorization decision pursuant to Section 438.210 of Title 42 of the Code of Federal Regulations.(e)For purposes of this section, Medi-Cal managed care plan means any individual, organization, or entity that enters into a contract with the department to provide services to enrolled Medi-Cal beneficiaries pursuant to any of the following:(1)Article 2.7 (commencing with Section 14087.3), including dental managed care programs developed pursuant to Section 14087.46.(2)Article 2.8 (commencing with Section 14087.5).(3)Article 2.81 (commencing with Section 14087.96).(4)Article 2.82 (commencing with Section 14087.98).(5)Article 2.9 (commencing with Section 14088).(6)Article 2.91 (commencing with Section 14089).(7)Chapter 8 (commencing with Section 14200), including dental managed care plans.(8)Chapter 8.9 (commencing with Section 14700).(9)A county Drug Medi-Cal organized delivery system authorized under the California Medi-Cal 2020 Demonstration, Number 11-W-00193/9, as approved by the federal Centers for Medicare and Medicaid Services and described in the Special Terms and Conditions. For purposes of this subdivision, Special Terms and Conditions shall have the same meaning as set forth in subdivision (o) of Section 14184.10.SEC. 5.SEC. 4.Section 14197.45 is added to the Welfare and Institutions Code, to read:14197.45.(a)A Medi-Cal managed care plan shall comply with all of the following:
(1)Make a good-faith effort to contract with at least one National Cancer Institute (NCI)-designated comprehensive cancer center, site affiliated with the NCI Community Oncology Research Program (NCORP), or qualifying academic cancer center, within its primary network for provision of services to any eligible enrollee diagnosed with a complex cancer diagnosis.
(2)Allow any eligible enrollee diagnosed with a complex cancer diagnosis to choose request a referral to receive services through an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.
(3)Allow After a referral pursuant to paragraph (2), allow an eligible enrollee diagnosed with a complex cancer diagnosis to directly access oncology, hematology, or other relevant specialists through an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center, as appropriate, for the enrollees condition and identified needs.
(4)Inform an enrollee within seven calendar days of the enrollee receiving a complex cancer diagnosis of the enrollees eligibility to ability to request a referral to receive cancer care at an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center, any restrictions on the enrollees choice to receive that care, and grievance, appeal, and fair hearing procedures and timeframes should the enrollees choice request for referral be denied. A Medi-Cal managed care plan shall also inform the enrollee of their ability to access transportation services if needed to access their care pursuant to subdivision (ad) of Section 14132.
(5)A denial of an enrollees referral request shall be based upon a determination by the treating provider that the request to receive services at an NCIdesignated comprehensive cancer center, or NCORP affiliated site, or a qualifying academic cancer center is not medically necessary, the requested services are not available at, or not applicable to, the enrollees cancer diagnosis at the requested NCI-designated comprehensive cancer center, NCORP affiliated site, or a qualifying academic cancer center site.
(5)(6)Ensure that the services of an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center available to an eligible enrollee are sufficient in amount, duration, and scope to reasonably achieve the purpose for which the services are furnished.
(6)(7)Refrain from arbitrarily denying or reducing the amount, duration, or scope of required services solely because of diagnosis, type of illness, or condition of the beneficiary.
(b)Contracts between Medi-Cal managed care plans and applicable health care providers shall require the treating provider who determines cancer stage or response to treatment to inform enrollees who receive a complex cancer diagnosis of the right to receive care through an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.(c)(b)(1)A Medi-Cal managed care plan shall provide written and verbal notice to all enrollees of their right to request a referral to access care through an a contracted NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center, if they are diagnosed with a complex cancer diagnosis.
(2)The department, in consultation with representatives of NCI-designated comprehensive cancer centers, NCORP-affiliated sites, qualifying academic cancer centers, patients or patient advocates, and Medi-Cal managed care plans, shall develop a standard written notice and process for verbally process for notifying enrollees of their right to request referral to access cancer treatment care through an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.
(d)(c)(1)Beginning January 1, 2023, each applicable Medi-Cal managed care plan shall reimburse an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center provider furnishing services to a Medi-Cal beneficiary with a complex cancer diagnosis enrolled in that plan, and each NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center shall accept the payment amount for those services, the amount set by the department upon consultation with the Medi-Cal managed care plans, NCI-designated comprehensive cancer centers, NCORP-affiliated sites, and qualifying academic cancer centers, if the Medi-Cal managed care plan and the NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center do not otherwise have an agreed-upon contracted rate.
(2)For contract periods during which paragraph (1) is implemented, capitation rates paid by the department to a Medi-Cal managed care plan shall be actuarially sound and shall account for the payment levels described in paragraph (1). The department may require Medi-Cal managed care plans and NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center providers to submit information the department deems necessary to implement this subdivision, at the times and in the form and manner specified by the department.
(3)For contract periods during which paragraph (1) is implemented, the department shall develop and implement risk mitigation strategies, such as a risk corridor or supplemental capitation payment. Risk mitigation strategies shall be developed in consultation with the Medi-Cal managed care plans and NCI-designated comprehensive cancer centers, NCORP-affiliated sites, and qualifying academic cancer centers.
(e)(d)For the purposes of this section, the following definitions apply:
(1)Complex cancer diagnosis means a diagnosis for which there is no standard FDA-approved treatment or for which known highly effective therapy for metastatic cancer has failed and any of the following diagnoses: hematological malignancies, acute leukemia, multiple myeloma, advanced, relapsed, refractory non-Hodgkin lymphoma, lymphoma and multiple myeloma, rare hematological malignancies malignancies, including BPDCN and T-cell leukemias and lymphomas, and solid tumors including pancreatic cancer, advanced-stage lung cancer, advanced-stage prostate cancer, advanced-stage breast cancer, sarcomas, liver, and biliary cancer, relapsed, refractory gastric cancer, advanced-stage relapsed, refractory colorectal cancer, advanced stage, relapsed solid tumors refractory to standard FDA-approved treatment options, advanced stage rare solid tumors for which there is no known effective standard treatment options, or any other condition as determined pursuant to subparagraph (B) of paragraph (1) of subdivision (f). (e). Advanced stage cancer means stage IV metastatic cancer.
(2)Eligible enrollee means an individual enrolled with a particular Medi-Cal managed care plan who receives a complex cancer diagnosis.
(3)National Cancer Institute (NCI) Community Oncology Research Program (NCORP) affiliated site is a cancer center that has received an approved grant from NCI through NCORP that provides cancer clinical trials and care delivery studies.
(4)NCI-designated comprehensive cancer center is a cancer center that meets ongoing standards for cancer prevention, clinical services, and research, as determined by regular reviews and evaluations by NCI.
(5)Qualifying academic cancer center is a research and clinical cancer center that meets all the following criteria:
(A)It is an institution with a medical oncology or hematology subspecialty expertise in each of the diagnoses included in paragraph (1).
(B)It has a portfolio of phases 1, 2, and 3 clinical trials for each of the cancer types included in paragraph (1).
(C)It provides fellowship programs in medical oncology, hematology or hematological oncology, radiation oncology, or a surgical oncology specialty.
(D)It provides inpatient and outpatient supportive care services.
(E)It covers clinical, anatomic, and molecular pathology with subspecialty expertise for each of the cancer types included in paragraph (1).
(F)It provides a program accredited by the American College of Surgeons (ACS) Commission on Cancer (CoC).
(G)It has accreditation for the main campus by the Foundation for the Accreditation of Cellular Therapy.
(f)(e)(1)(A)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section, in whole or in part, by means of all-county letters, plan letters, provider bulletins, information notices, or other similar guidance, until any necessary regulations are adopted.
(B)The department shall develop a process for updating and further defining a complex cancer diagnosis on a periodic basis. The process shall include an advisory committee consisting of experts in the field of oncology and stakeholders, including, but not limited to, oncologists, representatives of NCI-designated comprehensive cancer centers, NCORP-affiliated sites, and qualifying academic cancer centers, representatives of Medi-Cal managed care plans, and cancer patient advocacy groups.
(2)The department shall seek any federal approvals it deems necessary to implement this section. This section shall be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and is not otherwise jeopardized.
This act shall be known, and may be cited, as the California Cancer Care Equity Act.
SEC. 2.(a)The Legislature finds and declares all of the following:
(1)Effective treatment of complex cancers relies on the accuracy of initial diagnosis, timeliness of intervention, choice of therapy, collaboration among multiple experts, and access to appropriate clinical trials or emerging therapies.
(2)National Cancer Institute (NCI)-Designated Cancer Centers (NCI)-designated comprehensive cancer centers are recognized for their scientific leadership, resources, and exceptional depth and breadth of transdisciplinary research that bridges the fields of prevention, cancer control, and population science.
(3)The NCI Community Oncology Research Program (NCORP) is a national network that brings cancer clinical trials and care delivery studies to patients in their own communities and contributes to improved patient outcomes and a reduction in cancer disparities for all people.
(3)(4)Varying levels of access to quality cancer care correlated with socioeconomic status lead to disparities in cancer outcomes, disfavoring the most vulnerable and disadvantaged patients.
(b)It is the intent of the Legislature that a Medi-Cal managed care beneficiary who has received a complex cancer diagnosis will be eligible to receive and able to access the services of an NCI-Designated Cancer Center. NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.
SEC. 3.Section 14197.01 is added to the Welfare and Institutions Code, to read:14197.01.Notwithstanding any other law, for covered benefits under its contract, as applicable, a Medi-Cal managed care plan shall do both of the following:(a)Include in its contracted provider network at least one National Cancer Institute (NCI)-Designated Cancer Center located within the beneficiarys county of residence or, if none exists in that county, located within the nearest county that has an NCI-Designated Cancer Center.(b)Ensure that any beneficiary diagnosed with a complex cancer diagnosis, as defined in paragraph (1) of subdivision (e) of Section 14197.45, is referred to an NCI-Designated Cancer Center within 15 business days of the diagnosis, unless the beneficiary chooses a different cancer treatment provider.SEC. 3.Section 14197.01 is added to the Welfare and Institutions Code, to read:14197.01.(a)Notwithstanding any other law, for covered benefits under its contract, as applicable, a Medi-Cal managed care plan shall do both of the following:
(1)Make a good-faith effort to include in its contracted provider network at least one National Cancer Institute (NCI)-designated comprehensive cancer center, site affiliated with the NCI Community Oncology Research Program (NCORP), or qualifying academic cancer center, located within the beneficiarys county of residence or, if none exists in that county, located within the nearest county that has an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.
(2)Ensure that any beneficiary diagnosed with a complex cancer diagnosis is referred to an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center within 15 business days of the diagnosis, unless the beneficiary chooses a different cancer treatment provider.
(b)For purposes of this section, NCI-designated comprehensive cancer center, NCORP-affiliated site, qualifying academic cancer center, and complex cancer diagnosis shall have the same corresponding meanings as set forth in Section 14197.45.
SEC. 4.Section 14197.3 of the Welfare and Institutions Code is amended to read:14197.3.(a)A Medi-Cal managed care plan shall give a beneficiary timely and adequate notice of an adverse benefit determination in writing consistent with the requirements in Sections 438.404, 438.408, and 438.10, and 438.210 of Title 42 of the Code of Federal Regulations. For purposes of this subdivision, adverse benefit determination means either of the following:
(1)Any action described in Section 10950.
(2)Any health care service eligible for coverage and payment under a Medi-Cal managed care plan contract that has been denied, modified, or delayed by a decision of the Medi-Cal managed care plan, or by one of its contracting providers.
(b)Except as provided in subdivision (c), a Medi-Cal managed care plan shall resolve an appeal no more than 30 calendar days from the day the Medi-Cal managed care plan receives the appeal.
(c)A Medi-Cal managed care plan shall resolve an expedited appeal no longer than 72 hours after the Medi-Cal managed care plan receives the appeal. A Medi-Cal managed care plan shall establish and maintain an expedited review process for a beneficiary or the beneficiarys provider to request an expedited resolution of an appeal based on any of the following circumstances:
(1)If the Medi-Cal managed care plan determines, for a request from the beneficiary, or the provider indicates, in making the request on the beneficiarys behalf or supporting the beneficiarys request, that taking the time for a standard resolution under the timeframe described in subdivision (b) could seriously jeopardize the beneficiarys life, physical or mental health, or ability to attain, or regain, maximum function.
(2)When the beneficiarys condition is such that the beneficiary faces an imminent and serious threat to the beneficiarys health, including, but not limited to, the potential loss of life, limb, or other major bodily function, or the timeframe described in subdivision (b) would be detrimental to the beneficiarys life or health or could jeopardize the beneficiarys ability to regain maximum function.
(3)When a request from the beneficiary or provider is for, or related to, treatment pursuant to a complex cancer diagnosis, as defined in paragraph (1) of subdivision (e) of Section 14197.45.
(d)For purposes of paragraph (3) of subdivision (c), a Medi-Cal managed care plan shall give a request for, or related to, treatment pursuant to a complex cancer diagnosis, as defined in paragraph (1) of subdivision (e) of Section 14197.45, an expedited authorization decision pursuant to Section 438.210 of Title 42 of the Code of Federal Regulations.
(e)For purposes of this section, Medi-Cal managed care plan means any individual, organization, or entity that enters into a contract with the department to provide services to enrolled Medi-Cal beneficiaries pursuant to any of the following:
(1)Article 2.7 (commencing with Section 14087.3), including dental managed care programs developed pursuant to Section 14087.46.
(2)Article 2.8 (commencing with Section 14087.5).
(3)Article 2.81 (commencing with Section 14087.96).
(4)Article 2.82 (commencing with Section 14087.98).
(5)Article 2.9 (commencing with Section 14088).
(6)Article 2.91 (commencing with Section 14089).
(7)Chapter 8 (commencing with Section 14200), including dental managed care plans.
(8)Chapter 8.9 (commencing with Section 14700).
(9)A county Drug Medi-Cal organized delivery system authorized under the California Medi-Cal 2020 Demonstration, Number 11-W-00193/9, as approved by the federal Centers for Medicare and Medicaid Services and described in the Special Terms and Conditions. For purposes of this subdivision, Special Terms and Conditions shall have the same meaning as set forth in subdivision (o) of Section 14184.10.
SEC. 5.Section 14197.45 is added to the Welfare and Institutions Code, to read:14197.45.(a)Medi-Cal managed care plans shall comply with the following:(1)Make a good-faith effort to contract with at least one National Cancer Institute (NCI)-Designated Cancer Center within its primary network for provision of services to any eligible enrollee diagnosed with a complex cancer diagnosis.(2)Allow any eligible enrollee diagnosed with a complex cancer diagnosis to choose to receive services through an NCI-Designated Cancer Center.(3)Allow an eligible enrollee diagnosed with a complex cancer diagnosis to directly access oncology, hematology, or other relevant specialists through an NCI-Designated Cancer Center, as appropriate, for the enrollees condition and identified needs.(4)Inform an enrollee within seven calendar days of the enrollee receiving a complex cancer diagnosis of the enrollees eligibility to receive cancer care at an NCI-Designated Cancer Center, any restrictions on the enrollees choice to receive that care, and grievance, appeal, and fair hearing procedures and timeframes should the enrollees choice be denied. A Medi-Cal managed care plan shall also inform the enrollee of their ability to access transportation services if needed to access their care pursuant to subdivision (ad) of Section 14132.(5)Ensure that the services of an NCI-Designated Cancer Center available to an eligible enrollee are sufficient in amount, duration, and scope to reasonably achieve the purpose for which the services are furnished.(6)Refrain from arbitrarily denying or reducing the amount, duration, or scope of required services solely because of diagnosis, type of illness, or condition of the beneficiary.(b)Contracts between Medi-Cal managed care plans and primary care providers shall require the diagnosing or treating provider who determines cancer stage or response to treatment to inform enrollees who receive a complex cancer diagnosis of the right to receive care through an NCI-Designated Cancer Center.(c)(1)A Medi-Cal managed care plan shall provide written and verbal notice to all enrollees of their right to access care through an NCI-Designated Cancer Center if they are diagnosed with a complex cancer diagnosis.(2)The department, in consultation with representatives of NCI-Designated Cancer Centers, patients or patient advocates, and Medi-Cal managed care plans, shall develop a standard written notice and process for verbally notifying enrollees of their right to access cancer treatment care through an NCI-Designated Cancer Center.(d)(1)Beginning January 1, 2023, each applicable Medi-Cal managed care plan shall reimburse an NCI-Designated Cancer Center provider furnishing services to a Medi-Cal beneficiary with a complex cancer diagnosis enrolled in that plan, and each NCI-Designated Cancer Center shall accept the payment amount for those services, the amount set by the department upon consultation with the Medi-Cal managed care plans and the NCI-Designated Cancer Centers if the Medi-Cal managed care plan and the NCI-Designated Cancer Center do not otherwise have an agreed-upon contracted rate.(2)For contract periods during which paragraph (1) is implemented, capitation rates paid by the department to a Medi-Cal managed care plan shall be actuarially sound and shall account for the payment levels described in paragraph (1). The department may require Medi-Cal managed care plans and NCI-Designated Cancer Center providers to submit information the department deems necessary to implement this subdivision, at the times and in the form and manner specified by the department.(3)For contract periods during which paragraph (1) is implemented, the department shall develop and implement risk mitigation strategies, such as a risk corridor or supplemental capitation payment. Risk mitigation strategies shall be developed in consultation with the Medi-Cal managed care plans and NCI-Designated Cancer Centers.(e)For the purposes of this section, the following definitions apply:(1)Complex cancer diagnosis means a diagnosis for hematological malignancies, acute leukemia, multiple myeloma, advanced, relapsed, refractory non-Hodgkin lymphoma, rare hematological malignancies including BPDCN and T-cell leukemias and lymphomas, and solid tumors including pancreatic cancer, advanced-stage lung cancer, advanced-stage prostate cancer, advanced-stage breast cancer, sarcomas, liver, and biliary cancer, relapsed, refractory gastric cancer, advanced-stage relapsed, refractory colorectal cancer, or any other condition as determined pursuant to subparagraph (B) of paragraph (1) of subdivision (f). Advanced stage cancer means stage IV metastatic cancer.(2)Eligible enrollee means an individual enrolled with a particular Medi-Cal managed care plan who receives a complex cancer diagnosis.(f)(1)(A)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section, in whole or in part, by means of all-county letters, plan letters, provider bulletins, information notices, or other similar guidance, until any necessary regulations are adopted.(B)The department shall develop a process for updating and further defining a complex cancer diagnosis on a periodic basis. The process shall include an advisory committee consisting of experts in the field of oncology and stakeholders, including, but not limited to, oncologists, representatives of NCI-Designated Cancer Centers, representatives of Medi-Cal managed care plans, and cancer patient advocacy groups.(2)The department shall seek any federal approvals it deems necessary to implement this section. This section shall be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and is not otherwise jeopardized.SEC. 5.Section 14197.45 is added to the Welfare and Institutions Code, to read:14197.45.(a)A Medi-Cal managed care plan shall comply with all of the following:
(1)Make a good-faith effort to contract with at least one National Cancer Institute (NCI)-designated comprehensive cancer center, site affiliated with the NCI Community Oncology Research Program (NCORP), or qualifying academic cancer center, within its primary network for provision of services to any eligible enrollee diagnosed with a complex cancer diagnosis.
(2)Allow any eligible enrollee diagnosed with a complex cancer diagnosis to choose to receive services through an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.
(3)Allow an eligible enrollee diagnosed with a complex cancer diagnosis to directly access oncology, hematology, or other relevant specialists through an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center, as appropriate, for the enrollees condition and identified needs.
(4)Inform an enrollee within seven calendar days of the enrollee receiving a complex cancer diagnosis of the enrollees eligibility to receive cancer care at an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center, any restrictions on the enrollees choice to receive that care, and grievance, appeal, and fair hearing procedures and timeframes should the enrollees choice be denied. A Medi-Cal managed care plan shall also inform the enrollee of their ability to access transportation services if needed to access their care pursuant to subdivision (ad) of Section 14132.
(5)Ensure that the services of an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center available to an eligible enrollee are sufficient in amount, duration, and scope to reasonably achieve the purpose for which the services are furnished.
(6)Refrain from arbitrarily denying or reducing the amount, duration, or scope of required services solely because of diagnosis, type of illness, or condition of the beneficiary.
(b)Contracts between Medi-Cal managed care plans and applicable health care providers shall require the treating provider who determines cancer stage or response to treatment to inform enrollees who receive a complex cancer diagnosis of the right to receive care through an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.
(c)(1)A Medi-Cal managed care plan shall provide written and verbal notice to all enrollees of their right to access care through an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center, if they are diagnosed with a complex cancer diagnosis.
(2)The department, in consultation with representatives of NCI-designated comprehensive cancer centers, NCORP-affiliated sites, qualifying academic cancer centers, patients or patient advocates, and Medi-Cal managed care plans, shall develop a standard written notice and process for verbally notifying enrollees of their right to access cancer treatment care through an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center.
(d)(1)Beginning January 1, 2023, each applicable Medi-Cal managed care plan shall reimburse an NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center provider furnishing services to a Medi-Cal beneficiary with a complex cancer diagnosis enrolled in that plan, and each NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center shall accept the payment amount for those services, the amount set by the department upon consultation with the Medi-Cal managed care plans, NCI-designated comprehensive cancer centers, NCORP-affiliated sites, and qualifying academic cancer centers, if the Medi-Cal managed care plan and the NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center do not otherwise have an agreed-upon contracted rate.
(2)For contract periods during which paragraph (1) is implemented, capitation rates paid by the department to a Medi-Cal managed care plan shall be actuarially sound and shall account for the payment levels described in paragraph (1). The department may require Medi-Cal managed care plans and NCI-designated comprehensive cancer center, NCORP-affiliated site, or qualifying academic cancer center providers to submit information the department deems necessary to implement this subdivision, at the times and in the form and manner specified by the department.
(3)For contract periods during which paragraph (1) is implemented, the department shall develop and implement risk mitigation strategies, such as a risk corridor or supplemental capitation payment. Risk mitigation strategies shall be developed in consultation with the Medi-Cal managed care plans and NCI-designated comprehensive cancer centers, NCORP-affiliated sites, and qualifying academic cancer centers.
(e)For the purposes of this section, the following definitions apply:
(1)Complex cancer diagnosis means a diagnosis for hematological malignancies, acute leukemia, multiple myeloma, advanced, relapsed, refractory non-Hodgkin lymphoma, rare hematological malignancies including BPDCN and T-cell leukemias and lymphomas, and solid tumors including pancreatic cancer, advanced-stage lung cancer, advanced-stage prostate cancer, advanced-stage breast cancer, sarcomas, liver, and biliary cancer, relapsed, refractory gastric cancer, advanced-stage relapsed, refractory colorectal cancer, or any other condition as determined pursuant to subparagraph (B) of paragraph (1) of subdivision (f). Advanced stage cancer means stage IV metastatic cancer.
(2)Eligible enrollee means an individual enrolled with a particular Medi-Cal managed care plan who receives a complex cancer diagnosis.
(3)National Cancer Institute (NCI) Community Oncology Research Program (NCORP) affiliated site is a cancer center that has received an approved grant from NCI through NCORP that provides cancer clinical trials and care delivery studies.
(4)NCI-designated comprehensive cancer center is a cancer center that meets ongoing standards for cancer prevention, clinical services, and research, as determined by regular reviews and evaluations by NCI.
(5)Qualifying academic cancer center is a research and clinical cancer center that meets all the following criteria:
(A)It is an institution with a medical oncology or hematology subspecialty expertise in each of the diagnoses included in paragraph (1).
(B)It has a portfolio of phases 1, 2, and 3 clinical trials for each of the cancer types included in paragraph (1).
(C)It provides fellowship programs in medical oncology, hematology or hematological oncology, radiation oncology, or a surgical oncology specialty.
(D)It provides inpatient and outpatient supportive care services.
(E)It covers clinical, anatomic, and molecular pathology with subspecialty expertise for each of the cancer types included in paragraph (1).
(F)It provides a program accredited by the American College of Surgeons (ACS) Commission on Cancer (CoC).
(G)It has accreditation for the main campus by the Foundation for the Accreditation of Cellular Therapy.
(f)(1)(A)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section, in whole or in part, by means of all-county letters, plan letters, provider bulletins, information notices, or other similar guidance, until any necessary regulations are adopted.
(B)The department shall develop a process for updating and further defining a complex cancer diagnosis on a periodic basis. The process shall include an advisory committee consisting of experts in the field of oncology and stakeholders, including, but not limited to, oncologists, representatives of NCI-designated comprehensive cancer centers, NCORP-affiliated sites, and qualifying academic cancer centers, representatives of Medi-Cal managed care plans, and cancer patient advocacy groups.
(2)The department shall seek any federal approvals it deems necessary to implement this section. This section shall be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and is not otherwise jeopardized.
This act shall be known and may be cited known, and may be cited, as the California Cancer Care Equity Act.
SEC. 2.(a)The Legislature finds and declares all of the following:
(1)Effective treatment of complex cancers relies on the accuracy of initial diagnosis, timeliness of intervention, choice of therapy, collaboration among multiple experts, and access to appropriate clinical trials or emerging therapies.
(2)National Cancer Institute (NCI) Designated (NCI)-Designated Cancer Centers are recognized for their scientific leadership, resources, and exceptional depth and breadth of transdisciplinary research that bridges the fields of prevention, cancer control, and population science.
(3)Varying levels of access to quality cancer care correlated with socioeconomic status lead to disparities in cancer outcomes, disfavoring the most vulnerable and disadvantaged patients.
(b)It is the intent of the Legislature that a Medi-Cal managed care beneficiary who has received a complex cancer diagnosis will be eligible to receive and able to access the services of an NCI-Designated Cancer Center.
SEC. 3.Section 14197.01 is added to the Welfare and Institutions Code, to read:14197.01.Notwithstanding any other law, for covered benefits under its contract, as applicable, a Medi-Cal managed care plan shall do both of the following:
(a)Include in its contracted provider network at least one NCI-Designated National Cancer Institute (NCI)-Designated Cancer Center located within the beneficiarys county of residence or, if none exists in that county, located within the nearest county that has an NCI-Designated Cancer Center.
(b)Ensure that any beneficiary diagnosed with a complex cancer diagnosis, as defined in paragraph (1) of subdivision (e) of Section 14197.45, is referred to an NCI-Designated Cancer Center within 15 business days of the diagnosis, unless the beneficiary chooses a different cancer treatment provider.
SEC. 4.Section 14197.3 of the Welfare and Institutions Code is amended to read:14197.3.(a)A Medi-Cal managed care plan shall give a beneficiary timely and adequate notice of an adverse benefit determination in writing consistent with the requirements in Sections 438.404, 438.408, and 438.10, and 438.210 of Title 42 of the Code of Federal Regulations. For purposes of this subdivision, adverse benefit determination means either of the following:
(1)Any action described in Section 10950.
(2)Any health care service eligible for coverage and payment under a Medi-Cal managed care plan contract that has been denied, modified, or delayed by a decision of the Medi-Cal managed care plan, or by one of its contracting providers.
(b)Except as provided in subdivision (c), a Medi-Cal managed care plan shall resolve an appeal no more than 30 calendar days from the day the Medi-Cal managed care plan receives the appeal.
(c)A Medi-Cal managed care plan shall resolve an expedited appeal no longer than 72 hours after the Medi-Cal managed care plan receives the appeal. A Medi-Cal managed care plan shall establish and maintain an expedited review process for a beneficiary or the beneficiarys provider to request an expedited resolution of an appeal based on any of the following circumstances:
(1)If the Medi-Cal managed care plan determines, for a request from the beneficiary, or the provider indicates, in making the request on the beneficiarys behalf or supporting the beneficiarys request, that taking the time for a standard resolution under the timeframe described in subdivision (b) could seriously jeopardize the beneficiarys life, physical or mental health, or ability to attain, or regain, maximum function.
(2)When the beneficiarys condition is such that the beneficiary faces an imminent and serious threat to the beneficiarys health, including, but not limited to, the potential loss of life, limb, or other major bodily function, or the timeframe described in subdivision (b) would be detrimental to the beneficiarys life or health or could jeopardize the beneficiarys ability to regain maximum function.
(3)When a request from the beneficiary or provider is for or related to for, or related to, treatment pursuant to a complex cancer diagnosis, as defined in paragraph (1) of subdivision (e) of Section 14197.45.
(d)For purposes of paragraph (3) of subdivision (c), a Medi-Cal managed care plan shall give a request for, or related to, treatment pursuant to a complex cancer diagnosis, as defined in paragraph (1) of subdivision (e) of Section 14197.45, an expedited authorization decision pursuant to Section 438.210 of Title 42 of the Code of Federal Regulations.
(e)For purposes of this section, Medi-Cal managed care plan means any individual, organization, or entity that enters into a contract with the department to provide services to enrolled Medi-Cal beneficiaries pursuant to any of the following:
(1)Article 2.7 (commencing with Section 14087.3), including dental managed care programs developed pursuant to Section 14087.46.
(2)Article 2.8 (commencing with Section 14087.5).
(3)Article 2.81 (commencing with Section 14087.96).
(4)Article 2.82 (commencing with Section 14087.98).
(5)Article 2.9 (commencing with Section 14088).
(6)Article 2.91 (commencing with Section 14089).
(7)Chapter 8 (commencing with Section 14200), including dental managed care plans.
(8)Chapter 8.9 (commencing with Section 14700).
(9)A county Drug Medi-Cal organized delivery system authorized under the California Medi-Cal 2020 Demonstration, Number 11-W-00193/9, as approved by the federal Centers for Medicare and Medicaid Services and described in the Special Terms and Conditions. For purposes of this subdivision, Special Terms and Conditions shall have the same meaning as set forth in subdivision (o) of Section 14184.10.
SEC. 5.Section 14197.45 is added to the Welfare and Institutions Code, to read:14197.45.(a)Medi-Cal managed care plans shall comply with the following:
(1)Contract with at least one NCI-Designated Make a good-faith effort to contract with at least one National Cancer Institute (NCI)-Designated Cancer Center within its primary network for provision of services to any eligible enrollee diagnosed with a complex cancer diagnosis. A Medi-Cal managed care plan shall not delegate this requirement to a delegated entity within the Medi-Cal managed care plans network.
(2)Ensure that access to an NCI-Designated Cancer Center for any eligible enrollee diagnosed with a complex cancer diagnosis only occurs at the primary Medi-Cal managed care plan level. Enrollees may still access care through a different cancer provider at the delegated entity level, when assigned, if the beneficiary so chooses.(3)(2)Allow any eligible enrollee diagnosed with a complex cancer diagnosis to choose to receive services through an NCI-Designated Cancer Center that is in-network with the enrollees primary Medi-Cal managed care plan. Center.
(4)(3)Allow an eligible enrollee diagnosed with a complex cancer diagnosis to directly access oncology, hematology, or other relevant specialists through an NCI-Designated Cancer Center, as appropriate, for the enrollees condition and identified needs.
(5)(4)Inform an enrollee within seven calendar days of the enrollee receiving a complex cancer diagnosis of the enrollees eligibility to receive cancer care at an NCI-Designated Cancer Center, any restrictions on the enrollees choice to receive that care, and grievance, appeal, and fair hearing procedures and timeframes should the enrollees choice be denied. A Medi-Cal managed care plan shall also inform the enrollee of their ability to access transportation services if needed to access their care pursuant to subdivision (ad) of Section 14132.
(6)(5)Ensure that the services of an NCI-Designated Cancer Center available to an eligible enrollee are sufficient in amount, duration, and scope to reasonably achieve the purpose for which the services are furnished.
(7)(6)Refrain from arbitrarily denying or reducing the amount, duration, or scope of required services solely because of diagnosis, type of illness, or condition of the beneficiary.
(b)Contracts between Medi-Cal managed care plans and primary care providers shall require primary care physicians to inform enrollees who receive a complex cancer diagnosis of the enrollees health status, medical care, or treatment options, any information the enrollee needs to decide among all relevant treatment options, and the enrollees right to participate in decisions regarding their health care and to express preferences about future treatment decisions, including the right to receive care through an NCI-Designated Cancer Center.(b)Contracts between Medi-Cal managed care plans and primary care providers shall require the diagnosing or treating provider who determines cancer stage or response to treatment to inform enrollees who receive a complex cancer diagnosis of the right to receive care through an NCI-Designated Cancer Center.
(c)(1)A Medi-Cal managed care plan shall provide written and verbal notice to all enrollees of their right to access care through an NCI-Designated Cancer Center if they are diagnosed with a complex cancer diagnosis.
(2)The department, in consultation with representatives of NCI-Designated Cancer Centers, patients or patient advocates, and Medi-Cal managed care plans, shall develop a standard written notice and process for verbally notifying enrollees of their right to access cancer treatment care through an NCI-Designated Cancer Center.
(d)(1)For contract periods commencing on or after Beginning January 1, 2023, each applicable Medi-Cal managed care plan shall reimburse an NCI-Designated Cancer Center provider furnishing services to a Medi-Cal beneficiary with a complex cancer diagnosis enrolled in that plan, and each NCI-Designated Cancer Center shall accept the payment amount for those services, the amount of which would be paid for those services in the Medi-Cal fee-for-service delivery system, as defined by the department in the guidance issued pursuant to paragraph (1) of subdivision (f). set by the department upon consultation with the Medi-Cal managed care plans and the NCI-Designated Cancer Centers if the Medi-Cal managed care plan and the NCI-Designated Cancer Center do not otherwise have an agreed-upon contracted rate.
(2)For contract periods during which paragraph (1) is implemented, capitation rates paid by the department to a Medi-Cal managed care plan shall be actuarially sound and shall account for the payment levels described in paragraph (1). The department may require Medi-Cal managed care plans and NCI-Designated Cancer Center providers to submit information the department deems necessary to implement this subdivision, at the times and in the form and manner specified by the department.
(3)For contract periods during which paragraph (1) is implemented, the department shall develop and implement risk mitigation strategies, such as a risk corridor or supplemental capitation payment. Risk mitigation strategies shall be developed in consultation with the Medi-Cal managed care plans and NCI-Designated Cancer Centers.
(e)For the purposes of this section, the following definitions apply:
(1)Complex cancer diagnosis means a diagnosis for hematological malignancies, acute leukemia, multiple myeloma, advanced, relapsed, refractory non-Hodgkin lymphoma, rare hematological malignancies including BPDCN and T-cell leukemias and lymphomas, and solid tumors including pancreatic cancer, advanced-stage lung cancer, advanced-stage prostate cancer, advanced-stage breast cancer, sarcomas, liver, and biliary cancer. cancer, relapsed, refractory gastric cancer, advanced-stage relapsed, refractory colorectal cancer, or any other condition as determined pursuant to subparagraph (B) of paragraph (1) of subdivision (f). Advanced stage cancer means stage IV metastatic cancer.
(2)Delegated entity means an independent practitioner association or medical group or other entity contracted with a Medi-Cal managed care plan on a capitated basis for the provision of some or all of the Medi-Cal services being furnished to individuals enrolled in that delegated entity.(3)(2)Eligible enrollee means an individual enrolled with a particular Medi-Cal managed care plan who receives a complex cancer diagnosis.
(f)(1)(A)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section, in whole or in part, by means of all-county letters, plan letters, provider bulletins, information notices, or other similar guidance, without taking any further regulatory action. until any necessary regulations are adopted.
(B)The department shall develop a process for updating and further defining a complex cancer diagnosis on a periodic basis. The process shall include an advisory committee consisting of experts in the field of oncology and stakeholders, including, but not limited to, oncologists, representatives of NCI-Designated Cancer Centers, representatives of Medi-Cal managed care plans, and cancer patient advocacy groups.
(2)The department shall seek any federal approvals it deems necessary to implement this section. This section shall be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and is not otherwise jeopardized.
This act shall be known and may be cited as the California Cancer Care Equity Act.
SEC. 2.(a)The Legislature finds and declares all of the following:
(1)Effective treatment of complex cancers relies on the accuracy of initial diagnosis, timeliness of intervention, choice of therapy, collaboration among multiple experts, and access to appropriate clinical trials or emerging therapies.
(2)National Cancer Institute (NCI) Designated Cancer Centers are recognized for their scientific leadership, resources, and exceptional depth and breadth of transdisciplinary research that bridges the fields of prevention, cancer control, and population science.
(3)Varying levels of access to quality cancer care correlated with socioeconomic status lead to disparities in cancer outcomes, disfavoring the most vulnerable and disadvantaged patients.
(b)It is the intent of the Legislature that a Medi-Cal managed care beneficiary who has received a complex cancer diagnosis will be eligible to receive and able to access the services of an NCI-Designated Cancer Center.
SEC. 3.Section 14197.01 is added to the Welfare and Institutions Code, to read:14197.01.Notwithstanding any other law, for covered benefits under its contract, as applicable, a Medi-Cal managed care plan shall do both of the following:
(a)Include in its contracted provider network at least one NCI-Designated Cancer Center located within the beneficiarys county of residence or, if none exists in that county, located within the nearest county that has an NCI-Designated Cancer Center.
(b)Ensure that any beneficiary diagnosed with a complex cancer diagnosis, as defined in paragraph (1) of subdivision (e) of Section 14197.45, is referred to an NCI-Designated Cancer Center within 15 business days of the diagnosis, unless the beneficiary chooses a different cancer treatment provider.
SEC. 4.Section 14197.3 of the Welfare and Institutions Code is amended to read:14197.3.(a)A Medi-Cal managed care plan shall give a beneficiary timely and adequate notice of an adverse benefit determination in writing consistent with the requirements in Sections 438.404, 438.408, and 438.10 438.10, and 438.210 of Title 42 of the Code of Federal Regulations. For purposes of this subdivision, adverse benefit determination means either of the following:
(1)Any action described in Section 10950.
(2)Any health care service eligible for coverage and payment under a Medi-Cal managed care plan contract that has been denied, modified, or delayed by a decision of the Medi-Cal managed care plan, or by one of its contracting providers.
(b)Except as provided in subdivision (c), a Medi-Cal managed care plan shall resolve an appeal no more than 30 calendar days from the day the Medi-Cal managed care plan receives the appeal.
(c)A Medi-Cal managed care plan shall resolve an expedited appeal no longer than 72 hours after the Medi-Cal managed care plan receives the appeal. A Medi-Cal managed care plan shall establish and maintain an expedited review process for a beneficiary or the beneficiarys provider to request an expedited resolution of an appeal based on either any of the following circumstances:
(1)If the Medi-Cal managed care plan determines, for a request from the beneficiary, or the provider indicates, in making the request on the beneficiarys behalf or supporting the beneficiarys request, that taking the time for a standard resolution under the timeframe described in subdivision (b) could seriously jeopardize the beneficiarys life, physical or mental health, or ability to attain, or regain, maximum function.
(2)When the beneficiarys condition is such that the beneficiary faces an imminent and serious threat to his or her the beneficiarys health, including, but not limited to, the potential loss of life, limb, or other major bodily function, or the timeframe described in subdivision (b) would be detrimental to the beneficiarys life or health or could jeopardize the beneficiarys ability to regain maximum function.
(3)When a request from the beneficiary or provider is for or related to treatment pursuant to a complex cancer diagnosis, as defined in paragraph (1) of subdivision (e) of Section 14197.45.
(d)For purposes of paragraph (3) of subdivision (c), a Medi-Cal managed care plan shall give a request for, or related to, treatment pursuant to a complex cancer diagnosis, as defined in paragraph (1) of subdivision (e) of Section 14197.45, an expedited authorization decision pursuant to Section 438.210 of Title 42 of the Code of Federal Regulations.
(d)(e)For purposes of this section, Medi-Cal managed care plan means any individual, organization, or entity that enters into a contract with the department to provide services to enrolled Medi-Cal beneficiaries pursuant to any of the following:
(1)Article 2.7 (commencing with Section 14087.3), including dental managed care programs developed pursuant to Section 14087.46.
(2)Article 2.8 (commencing with Section 14087.5).
(3)Article 2.81 (commencing with Section 14087.96).
(4)Article 2.82 (commencing with Section 14087.98).
(5)Article 2.9 (commencing with Section 14088).
(6)Article 2.91 (commencing with Section 14089).
(7)Chapter 8 (commencing with Section 14200), including dental managed care plans.
(8)Chapter 8.9 (commencing with Section 14700).
(9)A county Drug Medi-Cal organized delivery system authorized under the California Medi-Cal 2020 Demonstration, Number 11-W-00193/9, as approved by the federal Centers for Medicare and Medicaid Services and described in the Special Terms and Conditions. For purposes of this subdivision, Special Terms and Conditions shall have the same meaning as set forth in subdivision (o) of Section 14184.10.
SEC. 5.Section 14197.45 is added to the Welfare and Institutions Code, to read:14197.45.(a)Medi-Cal managed care plans shall comply with the following:
(1)Contract with at least one NCI-Designated Cancer Center within its primary network for provision of services to any eligible enrollee diagnosed with a complex cancer diagnosis. A Medi-Cal managed care plan shall not delegate this requirement to a delegated entity within the Medi-Cal managed care plans network.
(2)Ensure that access to an NCI-Designated Cancer Center for any eligible enrollee diagnosed with a complex cancer diagnosis only occurs at the primary Medi-Cal managed care plan level. Enrollees may still access care through a different cancer provider at the delegated entity level, when assigned, if the beneficiary so chooses.
(3)Allow any eligible enrollee diagnosed with a complex cancer diagnosis to choose to receive services through an NCI-Designated Cancer Center that is in-network with the enrollees primary Medi-Cal managed care plan.
(4)Allow an eligible enrollee diagnosed with a complex cancer diagnosis to directly access oncology, hematology, or other relevant specialists through an NCI-Designated Cancer Center, as appropriate, for the enrollees condition and identified needs.
(5)Inform an enrollee within seven calendar days of the enrollee receiving a complex cancer diagnosis of the enrollees eligibility to receive cancer care at an NCI-Designated Cancer Center, any restrictions on the enrollees choice to receive that care, and grievance, appeal, and fair hearing procedures and timeframes should the enrollees choice be denied.
(6)Ensure that the services of an NCI-Designated Cancer Center available to an eligible enrollee are sufficient in amount, duration, and scope to reasonably achieve the purpose for which the services are furnished.
(7)Refrain from arbitrarily denying or reducing the amount, duration, or scope of required services solely because of diagnosis, type of illness, or condition of the beneficiary.
(b)Contracts between Medi-Cal managed care plans and primary care providers shall require primary care physicians to inform enrollees who receive a complex cancer diagnosis of the enrollees health status, medical care, or treatment options, any information the enrollee needs to decide among all relevant treatment options, and the enrollees right to participate in decisions regarding their health care and to express preferences about future treatment decisions, including the right to receive care through an NCI-Designated Cancer Center.
(c)(1)A Medi-Cal managed care plan shall provide written and verbal notice to all enrollees of their right to access care through an NCI-Designated Cancer Center if they are diagnosed with a complex cancer diagnosis.
(2)The department, in consultation with representatives of NCI-Designated Cancer Centers, patients or patient advocates, and Medi-Cal managed care plans, shall develop a standard written notice and process for verbally notifying enrollees of their right to access cancer treatment care through an NCI-Designated Cancer Center.
(d)(1)For contract periods commencing on or after January 1, 2023, each applicable Medi-Cal managed care plan shall reimburse an NCI-Designated Cancer Center provider furnishing services to a Medi-Cal beneficiary with a complex cancer diagnosis enrolled in that plan, and each NCI-Designated Cancer Center shall accept the payment amount for those services, the amount of which would be paid for those services in the Medi-Cal fee-for-service delivery system, as defined by the department in the guidance issued pursuant to paragraph (1) of subdivision (f).
(2)For contract periods during which paragraph (1) is implemented, capitation rates paid by the department to a Medi-Cal managed care plan shall be actuarially sound and shall account for the payment levels described in paragraph (1). The department may require Medi-Cal managed care plans and NCI-Designated Cancer Center providers to submit information the department deems necessary to implement this subdivision, at the times and in the form and manner specified by the department.
(3)For contract periods during which paragraph (1) is implemented, the department shall develop and implement risk mitigation strategies, such as a risk corridor or supplemental capitation payment. Risk mitigation strategies shall be developed in consultation with the Medi-Cal managed care plans and NCI-Designated Cancer Centers.
(e)For the purposes of this section, the following definitions apply:
(1)Complex cancer diagnosis means a diagnosis for hematological malignancies, acute leukemia, multiple myeloma, advanced, relapsed, refractory non-Hodgkin lymphoma, rare hematological malignancies including BPDCN and T-cell leukemias and lymphomas, and solid tumors including pancreatic cancer, advanced-stage lung cancer, advanced-stage prostate cancer, advanced-stage breast cancer, sarcomas, liver, and biliary cancer.
(2)Delegated entity means an independent practitioner association or medical group or other entity contracted with a Medi-Cal managed care plan on a capitated basis for the provision of some or all of the Medi-Cal services being furnished to individuals enrolled in that delegated entity.
(3)Eligible enrollee means an individual enrolled with a particular Medi-Cal managed care plan who receives a complex cancer diagnosis.
(f)(1)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section, in whole or in part, by means of all-county letters, plan letters, provider bulletins, information notices, or other similar guidance, without taking any further regulatory action.
(2)The department shall seek any federal approvals it deems necessary to implement this section. This section shall be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and is not otherwise jeopardized.
All matter omitted in this version of the bill appears in the bill as introduced in the Senate, February 14, 2022. (JR11)(a)It is the intent of the Legislature that the department implement and monitor compliance with the time and distance requirements set forth in Sections 438.68, 438.206, and 438.207 of Title 42 of the Code of Federal Regulations and this section, to ensure that all Medi-Cal managed care covered services are available and accessible to enrollees of Medi-Cal managed care plans in a timely manner, as those standards were enacted in May 2016.
(b)Commencing January 1, 2018, for covered benefits under its contract, as applicable, a Medi-Cal managed care plan shall maintain a network of providers that are located within the following time and distance standards for the following services:
(1)For primary care, both adult and pediatric, 10 miles or 30 minutes from the beneficiarys place of residence.
(2)For hospitals, 15 miles or 30 minutes from the beneficiarys place of residence.
(3)For dental services provided by a Medi-Cal managed care plan, 10 miles or 30 minutes from the beneficiarys place of residence.
(4)For obstetrics and gynecology primary care, 10 miles or 30 minutes from the beneficiarys place of residence.
(c)Commencing July 1, 2018, for the covered benefits under its contracts, as applicable, a Medi-Cal managed care plan shall maintain a network of providers that are located within the following time and distance standards for the following services:
(1)For specialists, as defined in subdivision (h), adult and pediatric, including obstetric and gynecology specialty care, as follows:
(A)Up to 15 miles or 30 minutes from the beneficiarys place of residence for the following counties: Alameda, Contra Costa, Los Angeles, Orange, Sacramento, San Diego, San Francisco, San Mateo, and Santa Clara.
(B)Up to 30 miles or 60 minutes from the beneficiarys place of residence for the following counties: Marin, Placer, Riverside, San Joaquin, Santa Cruz, Solano, Sonoma, Stanislaus, and Ventura.
(C)Up to 45 miles or 75 minutes from the beneficiarys place of residence for the following counties: Amador, Butte, El Dorado, Fresno, Kern, Kings, Lake, Madera, Merced, Monterey, Napa, Nevada, San Bernardino, San Luis Obispo, Santa Barbara, Sutter, Tulare, Yolo, and Yuba.
(D)Up to 60 miles or 90 minutes from the beneficiarys place of residence for the following counties: Alpine, Calaveras, Colusa, Del Norte, Glenn, Humboldt, Imperial, Inyo, Lassen, Mariposa, Mendocino, Modoc, Mono, Plumas, San Benito, Shasta, Sierra, Siskiyou, Tehama, Trinity, and Tuolumne.
(2)For pharmacy services, 10 miles or 30 minutes from the beneficiarys place of residence.
(3)For outpatient mental health services, as follows:
(A)Up to 15 miles or 30 minutes from the beneficiarys place of residence for the following counties: Alameda, Contra Costa, Los Angeles, Orange, Sacramento, San Diego, San Francisco, San Mateo, and Santa Clara.
(B)Up to 30 miles or 60 minutes from the beneficiarys place of residence for the following counties: Marin, Placer, Riverside, San Joaquin, Santa Cruz, Solano, Sonoma, Stanislaus, and Ventura.
(C)Up to 45 miles or 75 minutes from the beneficiarys place of residence for the following counties: Amador, Butte, El Dorado, Fresno, Kern, Kings, Lake, Madera, Merced, Monterey, Napa, Nevada, San Bernardino, San Luis Obispo, Santa Barbara, Sutter, Tulare, Yolo, and Yuba.
(D)Up to 60 miles or 90 minutes from the beneficiarys place of residence for the following counties: Alpine, Calaveras, Colusa, Del Norte, Glenn, Humboldt, Imperial, Inyo, Lassen, Mariposa, Mendocino, Modoc, Mono, Plumas, San Benito, Shasta, Sierra, Siskiyou, Tehama, Trinity, and Tuolumne.
(4)(A)For outpatient substance use disorder services other than opioid treatment programs, as follows:
(i)Up to 15 miles or 30 minutes from the beneficiarys place of residence for the following counties: Alameda, Contra Costa, Los Angeles, Orange, Sacramento, San Diego, San Francisco, San Mateo, and Santa Clara.
(ii)Up to 30 miles or 60 minutes from the beneficiarys place of residence for the following counties: Marin, Placer, Riverside, San Joaquin, Santa Cruz, Solano, Sonoma, Stanislaus, and Ventura.
(iii)Up to 60 miles or 90 minutes from the beneficiarys place of residence for the following counties: Alpine, Amador, Butte, Calaveras, Colusa, Del Norte, El Dorado, Fresno, Glenn, Humboldt, Imperial, Inyo, Kern, Kings, Lake, Lassen, Madera, Mariposa, Mendocino, Merced, Modoc, Monterey, Mono, Napa, Nevada, Plumas, San Benito, San Bernardino, San Luis Obispo, Santa Barbara, Shasta, Sierra, Siskiyou, Sutter, Tehama, Trinity, Tulare, Tuolumne, Yolo, and Yuba.
(B)For opioid treatment programs, as follows:
(i)Up to 15 miles or 30 minutes from the beneficiarys place of residence for the following counties: Alameda, Contra Costa, Los Angeles, Orange, Sacramento, San Diego, San Francisco, San Mateo, and Santa Clara.
(ii)Up to 30 miles or 60 minutes from the beneficiarys place of residence for the following counties: Marin, Placer, Riverside, San Joaquin, Santa Cruz, Solano, Sonoma, Stanislaus, and Ventura.
(iii)Up to 45 miles or 75 minutes from the beneficiarys place of residence for the following counties: Amador, Butte, El Dorado, Fresno, Kern, Kings, Lake, Madera, Merced, Monterey, Napa, Nevada, San Bernardino, San Luis Obispo, Santa Barbara, Sutter, Tulare, Yolo, and Yuba.
(iv)Up to 60 miles or 90 minutes from the beneficiarys place of residence for the following counties: Alpine, Calaveras, Colusa, Del Norte, Glenn, Humboldt, Imperial, Inyo, Lassen, Mariposa, Mendocino, Modoc, Mono, Plumas, San Benito, Shasta, Sierra, Siskiyou, Tehama, Trinity, and Tuolumne.
(d)(1)(A)A Medi-Cal managed care plan shall comply with the appointment time standards developed pursuant to Section 1367.03 of the Health and Safety Code, Section 1300.67.2.2 of Title 28 of the California Code of Regulations, subject to any authorized exceptions in Section 1300.67.2.2 of Title 28 of the California Code of Regulations, and the standards set forth in contracts entered into between the department and Medi-Cal managed care plans.
(B)Commencing July 1, 2018, subparagraph (A) applies to Medi-Cal managed care plans that are not, as of January 1, 2018, subject to the appointment time standards described in subparagraph (A).
(2)A Medi-Cal managed care plan shall comply with the following availability standards for skilled nursing facility services and intermediate care facility services, as follows:
(A)Within five business days of the request for the following counties: Alameda, Contra Costa, Los Angeles, Orange, Sacramento, San Diego, San Francisco, San Mateo, and Santa Clara.
(B)Within seven business days of the request for the following counties: Marin, Placer, Riverside, San Joaquin, Santa Cruz, Solano, Sonoma, Stanislaus, and Ventura.
(C)Within 14 calendar days of the request for the following counties: Amador, Butte, El Dorado, Fresno, Kern, Kings, Lake, Madera, Merced, Monterey, Napa, Nevada, San Bernardino, San Luis Obispo, Santa Barbara, Sutter, Tulare, Yolo, and Yuba.
(D)Within 14 calendar days of the request for the following counties: Alpine, Calaveras, Colusa, Del Norte, Glenn, Humboldt, Imperial, Inyo, Lassen, Mariposa, Mendocino, Modoc, Mono, Plumas, San Benito, Shasta, Sierra, Siskiyou, Tehama, Trinity, and Tuolumne.
(3)A county Drug Medi-Cal organized delivery system shall provide an appointment within three business days to an opioid treatment program.
(4)A dental managed care plan shall provide an appointment within four weeks of a request for routine pediatric dental services and within 30 calendar days of a request for specialist pediatric dental services.
(e)(1)The department, upon request of a Medi-Cal managed care plan, may authorize alternative access standards for the time and distance standards established under this section if either of the following occur:
(A)The requesting Medi-Cal managed care plan has exhausted all other reasonable options to obtain providers to meet the applicable standard.
(B)The department determines that the requesting Medi-Cal managed care plan has demonstrated that its delivery structure is capable of delivering the appropriate level of care and access.
(2)If a Medi-Cal managed care plan cannot meet the time and distance standards set forth in this section, the Medi-Cal managed care plan shall submit a request for alternative access standards to the department, in the form and manner specified by the department. A request may be submitted at the same time as the Medi-Cal managed care plan submits its annual demonstration of compliance with time and distance standards, if known at that time.
(3)A request for alternative access standards shall be approved or denied on a ZIP Code and provider type, including specialty type, basis by the department within 90 days of submission of the request. The Medi-Cal managed care plan shall also include a description of the reasons justifying the alternative access standards based on those facts and circumstances. Effective no sooner than contract periods commencing on or after July 1, 2020, the Medi-Cal managed care plan shall include a description on how the Medi-Cal managed care plan intends to arrange for beneficiaries to access covered services if the health care provider is located outside of the time and distance standards specified in subdivision (c). The department may stop the 90-day timeframe, on one or more occasions as necessary, in the event of an incomplete submission or to obtain additional information from the Medi-Cal managed care plan requesting the alternative access standards. Upon submission of sufficient additional information to the department, the 90-day timeframe shall resume at the same point in time it was previously stopped, except if there is less than 30 days remaining in which case the department shall approve or deny the request within 30 days of submission of sufficient additional information. If the department rejects the Medi-Cal managed care plans proposal, the department shall inform the Medi-Cal managed care plan of the departments reason for rejecting the proposal. The department shall post any approved alternative access standards on its internet website.
(4)The department may authorize a Medi-Cal managed care plan to use clinically appropriate telecommunications technology as a means of determining annual compliance with the time and distance standards established pursuant to this section or may approve alternative access to care, including telehealth consistent with the requirements of Section 2290.5 of the Business and Professions Code, e-visits, or other evolving and innovative technological solutions that are used to provide care from a distance.
(5)As part of the departments evaluation of a request submitted by a Medi-Cal managed care plan to utilize an alternative access standard pursuant to this subdivision, the department shall evaluate and determine whether the resulting time and distance is reasonable to expect a beneficiary to travel to receive care.
(f)(1)Effective for contract periods commencing on or after July 1, 2018, a Medi-Cal managed care plan shall, on an annual basis and when requested by the department, demonstrate to the department the Medi-Cal managed care plans compliance with the time and distance and appointment time standards developed pursuant to this section. The report shall measure compliance separately for adult and pediatric services for primary care, behavioral health, and core specialist services.
(2)Effective for contract periods commencing on or after July 1, 2020, the Medi-Cal managed care plan shall demonstrate, on an annual basis, and when requested by the department, to the department how the Medi-Cal managed care plan arranged for the delivery of Medi-Cal covered services to Medi-Cal enrollees, such as through the use of either Medi-Cal covered transportation or clinically appropriate telecommunications technology, as specified in paragraph (4) of subdivision (e), if the enrollees of a Medi-Cal managed care plan needed to obtain health care services from a health care provider or a facility located outside of the time and distance standards, as specified in subdivision (c).
The report shall measure compliance separately for adult and pediatric services for primary care, behavioral health, and core specialist services.
(3)Effective for contract periods commencing on or after July 1, 2018, the department shall evaluate on an annual basis a Medi-Cal managed care plans compliance with the time and distance and appointment time standards implemented pursuant to this section. This evaluation may include, but need not be limited to, annual and random surveys, investigation of complaints, grievances, or other indicia of noncompliance. Nothing in this subdivision shall be construed to limit the appeal rights of a Medi-Cal managed care plan under its contracts with the department.
(4)The department shall publish annually on its internet website a report that details the departments findings in evaluating a Medi-Cal managed care plans compliance under paragraph (2). At a minimum, the department shall specify in this report those Medi-Cal managed care plans, if any, that were subject to a corrective action plan due to noncompliance with the time and distance and appointment time standards implemented pursuant to this section during the applicable year and the basis for the departments finding of noncompliance. The report shall include a Medi-Cal managed care plans response to the corrective plan, if available.
(g)The department shall consult with Medi-Cal managed care plans, including mental health plans, health care providers, consumers, providers and consumers of long-term services and supports, and organizations representing Medi-Cal beneficiaries in the implementation of the requirements of this section.
(h)For purposes of this section, the following definitions apply:
(1)Medi-Cal managed care plan means any individual, organization, or entity that enters into a contract with the department to provide services to enrolled Medi-Cal beneficiaries pursuant to any of the following:
(A)Article 2.7 (commencing with Section 14087.3), including dental managed care programs developed pursuant to Section 14087.46.
(B)Article 2.8 (commencing with Section 14087.5).
(C)Article 2.81 (commencing with Section 14087.96).
(D)Article 2.82 (commencing with Section 14087.98).
(E)Article 2.9 (commencing with Section 14088).
(F)Article 2.91 (commencing with Section 14089).
(G)Chapter 8 (commencing with Section 14200), including dental managed care plans.
(H)Chapter 8.9 (commencing with Section 14700).
(I)A county Drug Medi-Cal organized delivery system authorized under the California Medi-Cal 2020 Demonstration pursuant to Article 5.5 (commencing with Section 14184) or a successor demonstration or waiver, as applicable.
(2)Specialist means any of the following:
(A)Cardiology/interventional cardiology.
(B)Nephrology.
(C)Dermatology.
(D)Neurology.
(E)Endocrinology.
(F)Ophthalmology.
(G)Ear, nose, and throat/otolaryngology.
(H)Orthopedic surgery.
(I)Gastroenterology.
(J)Physical medicine and rehabilitation.
(K)General surgery.
(L)Psychiatry.
(M)Hematology.
(N)Oncology.
(O)Pulmonology.
(P)HIV/AIDS specialists/infectious diseases.
(i)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department, without taking any further regulatory action, may implement, interpret, or make specific this section by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions until the time regulations are adopted.
(j)The department shall seek any federal approvals it deems necessary to implement this section. This section shall be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and is not otherwise jeopardized.
(k)This section shall remain in effect only until January 1, 2023, and as of that date is repealed, unless a later enacted statute that is enacted before January 1, 2023, deletes or extends that date.(k)This section shall remain in effect only until January 1, 2028, and as of that date is repealed.
|
Date
|
Status
|
|---|---|
| Sep 27, 2022 | Chaptered by Secretary of State. Chapter 608, Statutes of 2022. |
| Sep 27, 2022 | Approved by the Governor. |
| Sep 13, 2022 | Enrolled and presented to the Governor at 3 p.m. |
| Aug 31, 2022 | Assembly amendments concurred in. (Ayes 40. Noes 0. Page 5370.) Ordered to engrossing and enrolling. |
| Aug 29, 2022 | In Senate. Concurrence in Assembly amendments pending. |
| Aug 29, 2022 | Read third time. Passed. Ordered to the Senate. |
| Aug 25, 2022 | Read third time and amended. |
| Aug 15, 2022 | Read second time. Ordered to third reading. |
| Aug 11, 2022 | From committee: Do pass. (Ayes 14. Noes 0.) (August 11). |
| Aug 11, 2022 | Joint Rule 62(a) suspended. |
| Aug 10, 2022 | August 10 set for first hearing. Placed on suspense file. |
| Jul 29, 2022 | August 3 hearing postponed by committee. |
| Jun 30, 2022 | Read second time and amended. Re-referred to Com. on APPR. |
| Jun 29, 2022 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 14. Noes 0.) (June 28). |
| Jun 20, 2022 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| May 27, 2022 | Referred to Com. on HEALTH. |
| May 25, 2022 | In Assembly. Read first time. Held at Desk. |
| May 24, 2022 | Read third time. Passed. (Ayes 34. Noes 0. Page 3868.) Ordered to the Assembly. |
| May 19, 2022 | From committee: Do pass. (Ayes 6. Noes 1. Page 3778.) (May 19). |
| May 13, 2022 | Set for hearing May 19. |
| May 9, 2022 | May 9 hearing: Placed on APPR suspense file. |
| Apr 29, 2022 | Set for hearing May 9. |
| Apr 25, 2022 | Read second time and amended. Re-referred to Com. on APPR. |
| Apr 21, 2022 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 8. Noes 0. Page 3461.) (April 20). |
| Mar 30, 2022 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| Mar 29, 2022 | Set for hearing April 20. |
| Feb 23, 2022 | Referred to Com. on HEALTH. |
| Feb 15, 2022 | From printer. |
| Feb 14, 2022 | Introduced. Read first time. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 31, 2022 | Unfinished Business SB987 Portantino et al. Concurrence | Senate Floor |
Passed |
|
| Aug 29, 2022 | SB 987 Portantino Senate Third Reading By Blanca Rubio | Assembly Floor |
Passed |
|
| May 24, 2022 | Senate 3rd Reading SB987 Portantino | Senate Floor |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
Bill Author
Bill Co-Author(s):